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ABSTRACT
Cardiovascular disease (CVD) is the leading cause of death worldwide affecting
approximately 40% of all adults over the age of 20 and is responsible for an economic
burden upwards of $3 billion annually. Treatments for CVD are limited to either
hypertension medication to treat symptoms, and/or statin-based drugs to reduce lowdensity lipoprotein (LDL) cholesterol formation. However, recent studies suggest that
approximately 50% of patients diagnosed with CVD have normal to low LDL cholesterol
levels. Therefore, a critical need exists to develop new treatments for CVD that are
independent of cholesterol lowering statins. Fortilin, also known as translationally
controlled tumor protein (TCTP), is a 19kDa, 172 amino acid cytosolic protein
ubiquitously expressed in all cell types, at all stages of life. Fortilin overexpression in
arterial walls has been shown to propagate atherosclerotic plaque formation, a major
component of CVD. Fortilin is therefore a promising target for the rational design of
drugs to prevent formation of new plaques.
For a structure-based drug development process, recombinant protein is required
to characterize potential protein-drug interactions. Recombinant expression and
purification of fortilin has proven to be effectual, provided any affinity tag used for
purification is not cleaved. Here, we designed several constructs of recombinant fortilin
fusion protein and were the first to successfully cleave the affinity tag, making structural
activity studies more meaningful due to greater semblance to the native protein. Our new
construct, GGS-fortilin, can be produced in high yield with greater than 85% tag
vi

cleavage, but still contains the three amino acid linkers at the N-terminus. To determine
whether these three amino acids, Gly-Gly-Ser interfered with small molecule inhibitor
(SMI) binding, loop constructs were designed, wherein the affinity tag, a Strep-Tactin
peptide with the sequence WSHPQFEK, was placed at either the C terminal side of
Arg37, Ser46 or Gly56 within the flexible loop of fortilin’s highly conserved structure
and activity validated via calcium titration. Structural analysis and SMI binding studies
were performed for the loop constructs using circular dichroism (CD) and nuclear
magnetic resonance (NMR) spectroscopy.
NMR spectroscopy is a dynamic tool used in structure-based drug development to
characterize the structure of recombinantly expressed protein and to determine binding
sites for SMIs. The results presented here portend to the development of novel fortilin
constructs and structural studies with SMIs. Structural integrity was validated for the loop
constructs using CD and NMR, and activity validated with an NMR calcium binding
assay. Binding studies were also attempted using differential scanning fluorimetry (DSF)
and NMR.
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CHAPTER ONE: INTRODUCTION
1.1 The Drug Discovery Process: Drug Repurposing in Cardiovascular Disease
Section 1.1 published in Pharmaceuticals (Open Access)
Maranda S. Cantrell1,2, Alejandro Soto-Avellaneda1,3, Jackson D. Wall2, Aaron D.
Ajeti2, Brad E. Morrison3, Owen M. McDougal1 and Lisa R. Warner1
1
2

Biomolecular Sciences Ph. D. Program, Boise State University,

Department of Chemistry and Biochemistry, Boise State University
3

Department of Biology, Boise State University

1.1.1 Introduction
Drug development is a long, labor-intensive process with no guarantee of success.
On average, it takes 10 years and 2.6 billion dollars to develop a new drug, with success
rates averaging only about 12%.1 One way to mitigate the barriers of drug development is
to repurpose Food and Drug Administration (FDA) approved drugs for the treatment of
different diseases. Drug repurposing is the practice of finding new uses for existing drugs
at any stage of development. The benefit of drug repurposing is that the risk of failure is
significantly lower than drug development, which permits more effective use of resources
to optimize drug efficacy for treatment of the desired ailment. Much of the primary
research regarding repurposed drug safety, mechanism, and dosage has already been
completed at the time the drug was first studied.2 For example, a drug that demonstrated
efficacy in animal models with low side effects but failed in human clinical trials to
perform its intended purpose, may be a good candidate for use as a therapeutic for a
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different disease. Drugs with potential to be repurposed have progressed through many of
the steps required to meet regulatory safety and potency benchmarks, allowing for an
accelerated and abbreviated path to FDA approval. A few representative examples of
successful drugs that have been repurposed include amantadine, acetylsalicylic acid,
mecamylamine, minoxidil, and tamoxifen (Table 1).3 Repurposed drugs are generally
screened by computer search algorithms from databases of therapeutics that may or may
not have been sufficiently effective in providing treatment for the pathology that served
as their original target. For example, some drugs lack sufficient drug-like qualities to
warrant further investigation for treatment of an intended illness, but modification of the
molecular scaffold or functional groups attached to the drug template may afford
attributes and activity suitable for therapeutic viability. The therapeutic index for a
repurposed drug requires investigation into dosage recommendations for maximal benefit
to counter the illness, while minimizing detrimental side-effects to the patient.
Table 1.1

Examples of some FDA-approved repurposed drugs.

Drug
Amantadine
Acetylsalicylic
acid

Original purpose
Parkinson’s disease

Repurposed use
Influenza A

Reference
4

Inflammation, pain relief

Anti-platelet

5

Cyclosporine

Rheumatoid arthritis

Minoxidil

Hypertension
Chronic myelogous
leukemia

Imatinib

Transplant rejection,
psoriasis, chronic dry
eye
Alopecia
Gastrointestinal
stromal tumor

6
7
8

1.1.1.a Technology to repurpose drugs
Computational screening of previously marketed drugs to identify drug repurposing
candidates can lead researchers to initiate new clinical trials for treatment of alternative
ailments. Multiple computational strategies have emerged to identify potential candidates
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for drug repurposing. Of these, four strategies have gained popularity in recent years and
will be discussed in brief. These strategies are side effect similarity mapping, genome-wide
association studies (GWAS), small-molecule peptide-influenced drug repurposing
(SPIDR), and computational high throughput screening (HTS).9–11
In side-effect similarity mapping, existing drugs are categorized by their side
effects using the Unified Medical Language System (UMLS) ontology for medical
symptoms. Developed by Campillos et al. (2008), 746 marketed drugs were organized
according to their listed phenotypic side effect similarities rather than a chemical similarity,
and 20 of these marketed drugs were confirmed through in vitro assays to indicate that side
effect similarity may be indicative of common protein targets. Using this strategy,
prediction of the likelihood that two drugs had the same target based on their side effects
was demonstrated.12 This study describes a process by which drugs marketed for different
targets could be identified as having potential for repurposing.
GWAS identify single nucleotide polymorphisms (SNPs) and their associated
phenotypes for individuals with a given disease. GWAS is performed by genotyping
individuals which share a common disease and determining whether a genetic variant is
shared to statistical significance among this population. Experimental validation by
chromatin precipitation is then performed and variants are associated by phenotypic
effects.13 This technique has been used to identify many novel variants to trait associations
in a variety of diseases such as macular degeneration, anorexia nervosa, depression,
coronary artery disease and diabetes mellitus, and can be used to determine novel drug
targets as well.13,14 For example, GWAS have been used to identify SNPs for Parkinson’s
disease (PD) and determined that estradiol may protect dopaminergic neurons in PD. This
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supported previous evidence that estradiol may be protective against PD because men are
more likely to be diagnosed.15 The neuroprotective role of estradiol was later confirmed in
in vivo studies. At present, estradiol is still not an approved treatment for PD, but efficacy
studies are ongoing.2,16,17 Another example of GWAS being useful for determining novel
drug targets was the identification of a gene encoding a disintegrin and metalloproteinase
with thrombospondin motifs TS7 (ADAMTS7), a gene implicated in coronary artery
disease (CAD) for its presence in angiographic CAD patients and role in smooth muscle
cell migration, a finding that supports the idea of genetically inherited CAD.18,19 Using
GWAS, it is possible to identify new potential targets based on SNPs.
SPIDR is a recently developed computational screening technique to identify drugs
that can target a specific receptor by looking at its peptide ligand conformational space.11
This method was integrated into the free program DockoMatic v 2.1, making this process
accessible to lower resourced institutions.20 This technique works by first utilizing the
genetic algorithm managed peptide mutant screening (GAMPMS) to search for peptide
mutants with high binding affinity to the receptor, and then this population of peptides is
moved over to the SimSearcher utility to identify the best small molecules analogous to the
peptide population for binding to the isoform.11 SPIDR was developed and used to find 12
small molecules computationally predicted to bind with high affinity to a nicotinic
acetylcholine receptor (nAChR) isoform associated with Alzheimer’s and PD, by looking
at α-conotoxin MII peptide analogs that would bind favorably to the receptor isoform
specifically.11 Following this publication, a qualitative assay to detect dopamine release by
ligand action on nAChRs was developed with the intent to assess bioactivity of molecules
that may act on different nAChR isoforms for drug development. This assay was created

5
using a luminescence-based assay and validated with known nAChR binders:
acetylcholine, nicotine and cytosine.21 The PC-12 cell-based assay was intended to be used
to test the small molecules found in the SPIDR development publication for nAChR
activity as an in vitro validation for the SPIDR methodology.
Additionally, small molecule compound screens can be used to identify drugs
amenable to being repurposed. Computational programs such as AutoDock Vina are often
used to screen molecular library databases like ZINC, chEMBL, pubchem, DrugBank, and
others.22–24 Computational screens of small molecule databases are an ideal starting point
for any drug discovery project to narrow down a list of compounds that may bind a
biological target with high affinity. However, wet lab experimentation needs to be
conducted, which can be done with commercially available libraries of drugs using in vitro
cell-based assays. Researchers study whether a drug induces a phenotypic effect in cellbased assays, which are usually performed in cell culture or on a model organism whereas
a target-based screen can be performed in vitro using techniques like enzyme-linked
immunosorbent assay (ELISA), surface plasmon resonance (SPR) or nuclear magnetic
resonance (NMR) spectroscopy. Many reviews have been recently published on the topic
of drug repurposing in either CVD or neurodegeneration.25–31 However, there is little
explored in the realm of drugs that may be repurposed to target inflammatory processes
which link these two diseases. In this article we will briefly discuss strategies for
repurposing drugs and examples of drugs that are being repurposed for treatment of
cardiovascular disease and neurodegenerative disorders. Specifically, we will cover those
conditions that affect both cardiovascular and neurodegenerative disease such as
inflammatory pathways, which are intimately connected in both heart and brain disease.
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Currently, repurposed drugs are being used in studies associated with two cardiovascular
related diseases that include endothelial dysfunction and pulmonary arterial hypertension.
In neurodegenerative diseases, repurposed drugs are being studied for the treatment of
autophagy and neuroinflammation (Table 2).
Table 1.2.
Examples of drug or drug targets that have been identified using
computational methods.
Drug or target Target pathology Research method
kinase inhibitors Alzheimer’s disease machine learning
dopaminergic
machine learning
Parkinson’s disease
agonists
beta-secretase 1
data mining
Alzheimer’s diseases
inhibitors
Gastrointestinal
high throughput
GIST-T1 cells
stromal tumor
synergy screening

Reference
26
32
33

1.1.2 Targeting endothelial dysfunction in cardiovascular diseases
Cardiovascular diseases include atherosclerosis, coronary artery disease and
arrhythmias that eventually lead to myocardial infarction and/or stroke. Ischemic events
such as these are the leading cause of death in the world.34 Pharmacological intervention
of cardiovascular diseases is provided by statins, beta-blockers, and angiotensin
converting enzyme inhibitors. In more advanced cases, surgical intervention may be
necessary. The medications for cardiovascular disease target high cholesterol and lowdensity lipoprotein levels, and hypertension. There is an emerging field of research to
discover small molecule inhibitors for alternative pathways aimed at the disruption of
heart disease progression.35 There is a robust market for pharmaceutical companies to
synthesize drugs to treat disorders, but the potential for repurposing already FDAapproved drugs constitutes a desirable alternative to discovery since these medications
have been deemed safe enough for patient use and thus make clinical trials for novel use
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less trivial.
The endothelium is characterized by the cells of the tissue lining the various
organs of the body, including the arteries and lymphatic system. The endothelium plays a
major role in blood flow and constriction by facilitating the synthesis and degradation of
vasodilating factors, such as nitric oxide (NO), arachidonic acid metabolites and reactive
oxygen species (ROS).36 Endothelial dysfunction occurs when the endothelium fails to
function properly. Namely, that the endothelium dysfunctions in the formation of
vasodilating factors. Endothelial dysfunction is especially important in cardiovascular
disease because it is a leading contributor to cardiac events. Endothelial dysfunction is a
component of atherosclerosis, which is characterized by the hardening and narrowing of
the arterial walls, and hyperlipidemia, or high lipid concentrations in the blood.
Three drugs investigated for their potential to treat diseases of endothelial
dysfunction that will be discussed here include colchicine, which has been traditionally
used to treat gout, methotrexate, an immunosuppressant and chemotherapy drug, and
tocilizumab, an immunosuppressant used to treat severe rheumatoid arthritis.
1.1.2.a Colchicine
Colchicine is a secondary metabolite from the plants Gloriosa superba and
Colchicum autumnale, that is known to be toxic when ingested.37 Its current approved use
is to treat gout, an inflammatory form of arthritis common in people with high levels of
uric acid in their blood. Due to its anti-inflammatory properties, colchicine is currently
under investigation as a potential endothelial dysfunction drug. Endothelial dysfunction is
a characteristic of cardiovascular disease that leads to an increase in macrophages, T
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lymphocytes and growth factors that contribute to atherosclerotic lesion formation
associated with atherosclerosis.38–41 The same inflammation inhibition mechanism that
permits colchicine to be effective against gout, may also be applicable to the treatment of
patients with early stages of atherosclerosis.42,43
Colchicine prevents inflammation by binding to tubulin, preventing tubulin
polymerization and function (see Figure 1.1).18 As a result, colchicine halts mitotic cells
in metaphase. Colchicine also concentrates in neutrophils and prevents chemotaxis via
the release of crystal-derived chemotactic factor, and inhibits monosodium urate induced
loss of myeloid inhibitory C-type lectin-like receptor in neutrophils and interleukin-8
formation.44 Myeloid inhibitory C-type lectin-like receptor and interleukin-8 are
important in immune homeostasis and inflammatory response.45,46
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Figure 1.1. Inhibitory pathway of colchicine. Colchicine inhibits activation of
purinergic P2X2/P2X7 receptors and blocks cation uptake and subsequent proinflammatory signaling cascades without affecting cell death. Colchicine also
inhibits the NALP3 inflammasome pathway, the Rho/ROCK pathway via
cytoskeleton rearrangement, and inhibits release of ROS, NO and TNF. Figure 1.1
was created using BioRender.com (adapted from 44).
Cell adhesion is the process by which cells adhere to one another through the action
of proteins, electrostatic interactions, and hydrophobic interactions. Adhesion is
important because cells can use physical contact with one another to communicate via
signal transduction. Colchicine interferes with cell adhesion by inducing the shedding of
neutrophil adhesion molecules, which are important in neutrophil function.44 These
neutrophil adhesion molecules include selectins and counter receptors which partake in
signal transduction. Selectins are single-chain transmembrane glycoproteins organized by
leukocyte (L), endothelial (E) and platelet/endothelial (P) selectins. They are
characterized by their similar homology in both sequence, structure and sugar ligands.
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Colchicine reduces endothelial expression of selectins by acting on leukocytes in
coronary artery disease.43
Nidorf et al. reviewed ongoing clinical trial results and experimental evidence that
supported the use of colchicine as an anti-inflammatory drug with promising efficacy
toward the treatment of atherosclerosis.42 First, they describe the mechanisms by which
colchicine acts on the various inflammatory pathways including the production of proinflammatory cytokines, such as interleukin (IL)-1ß, reduction of platelet leukocyte
interactions that lead to atherothrombosis and suppressing the growth of fibroblasts and
osteophytes. At lower doses, colchicine was found to have no reported side effects on
patients with liver and/or kidney disease.42 The authors concluded that colchicine could
be repurposed for treatment of inflammation associated with atherosclerosis.
1.1.2.b Methotrexate
In the 1960’s, the National Institutes of Health reported that methotrexate (Figure
1.2) was effective at treating rheumatoid arthritis and psoriatic arthritis. However, the
rheumatology field at the time maintained a fidelity for corticosteroids to treat rheumatic
syndromes, which stifled the use of methotrexate. Subsequent studies were conducted,
establishing evidence that methotrexate was effective in the treatment of rheumatoid
arthritis.47
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Figure 1.2.

Chemical structure of methotrexate.

Methotrexate is a synthetic disease-modifying anti-rheumatic drug that is a
structural analog of folic acid.48 Methotrexate was originally used as a cancer drug but
has recently been investigated for its use in inflammation associated with endothelial
dysfunction. In a study of 673 patients, methotrexate was used for the treatment of
rheumatoid arthritis, and was determined that under proper dosing and use, it could be a
beneficial drug to treat arthritis with 1.7% adverse side effect frequency and 0.15%
mortality.49 Methotrexate was identified as a good candidate for use to treat inflammatory
diseases, including endothelial dysfunction.
Methotrexate exerts a multitude of biochemical and biological perturbations when
administered to patients. While the exact or primary mechanism of action is not
completely understood, multiple modes of activity have been characterized that reveal
how methotrexate functions (Figure 1.3). First, methotrexate diminishes the immune
response by increasing the rate of T cell apoptosis. Methotrexate binds dihydrofolate
reductase, causing an increase in nitric oxide synthase uncoupling through the prevention
of the conversion of dihydrobiopterin to tetrahydrobiopterin (Figure 1.3a). Second,
methotrexate suppresses inflammation and the immune response by promoting the release
of adenosine. Metabolites of methotrexate inhibit aminoimidazole-4-carboxamide
ribonucleotide (AICAR) transformylase, causing an increase in the concentration of
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intracellular AICAR and thus more adenosine release (Figure 1.3b). Third, methotrexate
increases the expression of long intergenic non-coding RNA p21, a mediator and
regulator of a variety of pro-apoptotic processes (Figure 1.3c).50

Figure 1.3. Metabolic pathways of methotrexate. a) Methotrexate inhibits
dihydrofolate reductase (DHFR) and prevents conversion of dihydrobiopterin
(BH2) to tetrahydrobiopterin (BH4), leading to uncoupling of NO synthase. b)
Methotrexate inhibits AICAR transformylase, leading to increased adenosine levels
and subsequent anti-inflammatory responses. c) Methotrexate stimulates lincRNAp21 expression, leading to increased apoptotic gene expression and subsequent antiinflammatory responses.
There is increasing evidence that the 5′-adenosine monophosphate-activated
protein kinase (AMPK) is beneficial to the endothelium by protecting against apoptosis,
oxidative stress and increases NO production in the endothelium, which reduces
cholesterol efflux activity.48 Stimulation of AMPK as a treatment for endothelial
dysfunction is under investigation. One study showed that application of methotrexate on
perivascular adipose tissue from Sprague-Dawley rats increased AMPK activity under
basal and inflammatory conditions when treated with a negative control, palmitic acid.48
A positive control using aminoimidazole-4-carboxamide ribonucleotide, a known AMPK
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agonist, was also able to stimulate AMPK activity. 48 This study similarly showed that
methotrexate stimulated adiponectin mRNA expression and suppressed the proinflammatory molecules nuclear factor kappa B (NFκB) p-65, tumor necrosis factor alpha
(TNF-α), and interleukin-6 (IL-6) activity.48 At the time of this review, only studies of
methotrexate on perivascular adipose tissue taken from sacrificed mice and in vitro
studies in cell culture have been performed, necessitating investigation into more
physiologically relevant in vivo model systems.
Contrarily, other studies have indicated that methotrexate may contribute to
vascular endothelial dysfunction by causing endothelial damage.51 Methotrexate is a
direct competitor with folic acid for the active site of human serum albumin, and indeed
folic acid supplements are often provided in conjunction with methotrexate to prevent
folic acid deficiency.52 A study performed in Wistar rats, by Sankrityayan in 2016,
showed that when administered with methotrexate, ex vivo vascular reactivity in the aorta
was significantly reduced.51 Vascular reactivity is the phenomenon responsible for both
vasoconstriction and vasodilation, and those responses to various stimuli implicated in
vasculature. Methotrexate has also been implicated in the reduction of NO, leading to
increased oxidative stress and hindering of bioavailability of tetrahydrobiopterin by
oxidizing it to dihydrobiopterin in the aorta.53,54 This leads to hypertension,
hyperlipidemia and induces endothelial dysfunction, because tetrahydrobiopterin is
necessary as a cofactor required for synthesis of NO.55
There is contradicting evidence for methotrexate use as an endothelial dysfunction
drug. On one hand, there is data that suggests methotrexate reduces inflammation, while
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on the other hand, methotrexate appears to lead to endothelial dysfunction. Therefore,
more studies must be performed to determine the true mechanism of action for
methotrexate on the vascular endothelium if it is to be used to treat endothelial
dysfunction. There are currently 2140 clinical trials listed under the National Library of
Medicine’s clinical trial database with methotrexate being evaluated for treatment of
everything from ectopic pregnancy, to schizophrenia, to alopecia, and cancer. It appears
that in many pathologies where inflammation is a principal concern, or where
immunomodulation is of utility, methotrexate may provide benefit.
1.1.2.c Tocilizumab
Tocilizumab (TCZ) is an IL-6 inhibitor and recombinant monoclonal antibody
used in rheumatoid arthritis treatment since obtaining FDA approval in 2010.56 TCZ
binds IL-6 and blocks JAK/STAT signaling to prevent the production of proinflammatory molecules.56,57 It is currently being investigated for the treatment of
endothelial dysfunction due to its anti-inflammatory properties. This is because RA is
often listed as a co-morbidity in approximately 39-50% of atherosclerosis-related deaths,
with endothelial dysfunction presented in many RA patients.58 One hypothesis is that the
release of networks of chromatin and granules (NETs) into the extracellular space, a
common occurrence in both RA and endothelial function. TCZ was found to alleviate
symptoms in endothelial dysfunction in a human clinical study.57
1.1.3 Targeting Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a relatively rare condition, affecting
approximately 10-52 people per million population, characterized by the narrowing of the
pulmonary arteries.59,60 Left untreated, pulmonary arterial hypertension leads to the
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buildup of pressure on the right side of the heart when blood vessels in the lungs are
diseased, causing the arteries to become increasingly narrow with time, and right-sided
heart failure, often resulting in premature death.61,62 While the direct cause of pulmonary
arterial hypertension is unknown, a set of factors including liver disease, HIV infection,
intravenous drug use, autoimmune disorders, and others are suspected to be culpable. For
pulmonary arterial hypertension, there are several drugs under investigation for use in
PAH in clinical trials and are discussed in detail.63 Of these, two drugs, Anakinra and
Tadalafil, target inflammatory processes specifically.
1.1.3.a Anakinra
Anakinra was approved for use in rheumatoid arthritis by the FDA in 2001.
Anakinra is currently under investigation and has undergone Phase I clinical trial studies
for novel use in PAH.63,64 Anakinra, an interleukin-1 (IL-1) receptor protein antagonist
analogue, is recombinantly expressed in E. coli and is administered via subcutaneous
injection. The proposed mechanism of action for PAH, done in mice, is such that
anakinra blocks perivascular macrophage recruitment in pulmonary artery smooth muscle
cells.65 In an inflammatory response pathway, IL-1β binds to IL-1 receptor (IL-1R) and
recruits the myeloid differentiation primary response protein 88 (MyD88) and induces
IL-1 synthesis via NFκB activation. In this study, the goal was to investigate whether this
pathway played a role in the progression of PAH.65 First, it was determined that in both
the lung tissue taken of patients with PAH as well as mice with PAH, there were
increased expression levels of both IL-1R and MyD88. In IL-1R-/- and MyD88-/- mice,
severity of PAH was not significantly different between the two but were significantly
lower in severity than hypoxic wild-type mice. Hypoxic wild-type mice treated with

16
anakinra (20 mg/kg per day) were shown to have lower severity in PAH symptoms,
namely, right ventricular systolic presser and hypertrophy, than untreated mice. It was
also observed than in both IL-1R-/- and MyD88-/- hypoxic mice as well as wild-type mice
treated with anakinra, there was no significant fold change in IL-1β levels when
compared to wild-type untreated mice with hypoxia over 48 hours. These findings
suggest that anakinra is a good potential treatment for PAH in that IL-1β is not having to
be expressed as an emergency measure for PAH. Furthermore, the pilot Phase I clinical
study (clinicaltrials.gov: NCT03057028) done with treatment of PAH by anakinra found
promising results by inducing IL-1 blockade.
1.1.3.b Tadalafil
Tadalafil is currently used to treat erectile dysfunction and benign prostatic
hyperplasia, and was approved by the FDA in 2009 for treatment of pulmonary arterial
hypertension.63,66Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor.67 PDE5
mRNA levels are mostly found in the cerebellum, kidney, pancreas, and rat lung tissues,
which may be indicative of human mRNA localization.68 The result, here, is such that
cyclic guanosine monophosphate (cGMP) concentrations are elevated and thus facilitate
the NO pathway, namely vasodilation.69 In brief, cGMP binds to PDE5 and increases
catalytic activity approximately 10-fold, leading to a decrease in protein kinase G (PKG)
stimulation and ultimately affecting vascular tone and growth in erectile dysfunction.70
The inhibition of PDE5 leads to elevated cGMP and NO levels.
The 16-week, double-blind, phase III clinical trial that led to FDA approval of
tadalafil for pulmonary arterial hypertension treatment consisted of 405 patients
diagnosed with PAH. The patients were given a prescribed dosage of tadalafil or placebo,
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and their performance to walk for 6-minutes was evaluated based on the distance they
covered.69 The findings of the study identified that an oral dosage of 40 mg per day of
tadalafil could improve exercise capability by an average of 33 m in patients with
pulmonary arterial hypertension versus the placebo patients. Dosage was weightdependent, though all patients weighed an average of 75 ± 22 kg in this study. Of the 357
patients that participated in a long-term study with tadalafil, 295 of them continued
treatment. While this study, along with other clinical trials, showed vast improvements in
patients with pulmonary arterial hypertension, the molecular mechanism by which
tadalafil acts as a therapeutic has yet to be elucidated.
1.1.4 Conclusion
The benefit of repurposing drugs that have previously been FDA approved
removes many of the time and financial barriers for bringing a drug to market. FDA
approval is a good indication of a drug’s effectiveness and safety in clinical trials, which
is indicative of a good outcome for the use of a drug for a different purpose. Because a
drug can take anywhere from 8-12 years to go from initial discovery to the market, drug
repurposing can cut this time significantly.1 The repurposing of drugs to treat
cardiovascular and neurodegenerative diseases is an emerging and promising field of
study. Treatments for inflammatory diseases including vascular endothelial dysfunction,
pulmonary arterial hypertension, multiple sclerosis, Parkinson’s and Alzheimer’s, using
repurposed drugs like colchicine, methotrexate, tocilizumab, felodipine, lonafarnib,
dimethyl fumarate and exemestane may prove to be an effective strategy to address the
treatment gap for untreatable ailments.
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1.2 A Review of Fortilin: Cellular Pathways, Functionality and Current Research
Efforts
1.2.1 Introduction
Fortilin, also known as p21, p23, histamine release factor (HRF), and
translationally controlled tumor protein (TCTP) is a cytosolic protein ubiquitously
expressed in all cell types and is prevalent during all stages of life.71 Since its initial
characterization in 2001, fortilin has been implicated in many diseases including many
cancers, malaria, CVD, pulmonary arterial hypertension (PAH), diabetes, and even some
developmental disorders.35 While fortilin has become recently recognized for its antiapoptotic function in the progression of disease, fortilin is also required for optimal cell
growth, cell proliferation, and cell cycle progression.72
Reviews to date focus on fortilin dysregulation in disease rather than the qualities
that make fortilin unique. Here, we discuss the structure of fortilin across different
species as well as the known cellular pathways of fortilin. We separate the known
pathways into anti-apoptotic and pro-survival for the reason that fortilin not only prevents
programmed cell death, but also contributes to cell proliferation during early
development. We conclude by outlining current research efforts for targeting fortilin
function in disease. The structure of fortilin is characterized by the N and C termini in
close proximity to one another, a hydrophobic core split into an α-helical region and a β
sheet region, and a flexible loop section (Figure 1.4).
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Figure 1.4. Structure of fortilin. The structure of fortilin consists of 172 amino
acids encompassing 3  helices (aqua), 3 anti-parallel  sheets consisting of 11 
strands (yellow) and several non-structured loops (orange) that connect the protein.
The flexible loop exists from T39 to V66. The N and C termini of fortilin are
proximal in location and form part of the  barrel comprised of  strands 1-4 and
8-11.
1.2.2 Structure of Fortilin: Characteristics and Cross-Species Homology
Fortilin is unique in both structure and sequence because it does not belong to any
classified family of proteins, though one study has shown that fortilin has some structural
similarity to guanine nucleotide-free chaperone protein Mss4 (Figure 1.5).73 As shown in
Figure 1.4, fortilin consists of 3 alpha helices and 11 beta sheets, of which 9 form a rigid
beta barrel. The structure of fortilin is quite rigid, with a flexible loop domain between
residues T39 and V66 in human fortilin. Fortilin also consists of a highly conserved
protein sequence across species and is found in all eukaryotic organisms, with a
molecular weight ranging from 19 to 23 kDa.74 Its taxonomic lineage can be traced
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among all domains of life, and cellular localization of fortilin is largely found in the
cytosol, though fortilin is also found in the nucleus.71 A representation of the sequence
homology is shown in Figure 1.6. This protein sequence homology corresponds to
physical structural conserved relationships amongst different species, namely the flexible
loop domain, for which a role in functionality has not yet been determined.

Figure 1.5. Structural similarities of fortilin and Mss4. Structural similarities
highlighted between A) human fortilin (PDB 2HR9) and B) human Mss4 (PDB
1FWQ) protein. Primary similarities include the α helix (orange), and beta sheets
(purple and yellow). Below is the protein sequence alignment for human fortilin and
human Mss4. Mss4 has approximately 23.8% sequence homology to fortilin using
LALIGN.75

21

Figure 1.6. Sequence homology of fortilin. Multiple sequence alignment of fortilin
protein in different species. Uniprot.org identifier is provided on the left with species
name. Residues highlighted in dark grey have 100% sequence homology while
residues highlighted in lighter greys have at least 50% sequence homology between
species analyzed.
The first solution structure of fortilin, also known as p23, was solved using
nuclear NMR spectroscopy in 2001 from the yeast strain Schizosaccharomyces pombe.73
The authors of this NMR study highlighted a structural similarity between fortilin and the
guanine nucleotide-free chaperone protein, mammalian suppressor of Sec4 (Mss4) in
their β-barrel structure, specifically (Figure 1.5). The key difference between S. pombe
TCTP and human fortilin are the length of protein and mass, 168 and 172 amino acids
and 19,049 and 19,595 Da, respectively. Cys172 forms a cysteine dimer of two fortilin
molecules via intermolecular disulfide bond.76 TCTP has since been both crystallized and
solution structures solved by NMR with protein data bank (PDB) structures provided in
Table 1.2.
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Table 1.2.

X-ray crystal and NMR solution structures of TCTP.

PDB Entry
2LOY
2KWB
1YZ1
2HR9
3EBM
509L/M
4Z9V
2MVM/N
6IZB/E
509K
6J2Y
3P3K
1TXJ
1H6Q/1H7Y

Method
NMR
NMR
X-ray
NMR
X-ray
X-ray
X-ray
NMR
X-ray
X-ray
NMR
X-ray
X-ray
NMR

Species
C. elegans
C. elegans
H. sapiens
H. sapiens
H. sapiens
H. sapiens
H. sapiens
H. sapiens
H. sapiens
M. musculus
N. oceanica
P. falciparum
P. knowlesi
S. pombe

Reference
77

Not yet published
78
79
80
81
82
83

Not yet published
81
84
85
86
73

The solution structure of human fortilin was solved by NMR spectroscopy in
2007.79 This study also characterized the calcium binding site of fortilin, where fortilin
had been previously described to play a role in calcium scavenging in calcium-dependent
apoptosis. In 2013, an X-ray crystallographic structure of TCTP from Plasmodium
falciparum was also characterized.87 The structure of fortilin is highly conserved across
species, as depicted in Figure 1.7.
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Figure 1.7. Structural homology of fortilin across species. PDB structures 2HR9
(sea green), 1H6Q (violet), 1YZ1 (tan), 2KWB (green), 3P3K (yellow) and 6J2Y
(red-orange) have been structurally aligned using UCSF Chimera v1.13.1.88
1.2.3 Known Functions of Fortilin: Anti-Apoptotic
Fortilin has many known functions both involving anti-apoptotic and cell growth
and proliferation functions (Figure 1.8). While much research focuses on fortilin’s antiapoptotic function, it is important to note that fortilin is also involved in many cell growth
and proliferation functions as well that do not necessarily involve preventing apoptosis.

Figure 1.8. Known cellular pathways of fortilin. A) PRX-1 binding (Chattopadhyay et al. 2016) B) IRE1 binding (Pinkaew
et al. 2017) C) p53 binding (Chen et al. 2011) D) calcium scavenging (Fujise et al. 2007) E) tubulin binding (Gachet et al. 1999)
F) Na+/K+ ATPAse and EFGR activity (Kim et al. 2009)
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1.2.3.a PRX1 Binding and Activity
Fortilin was found to bind peroxiredoxin-1 (PRX1) in vivo using an assay to
detect nicotinamide adenine dinucleotide phosphate (NADPH) consumption by PRX1.89
Peroxiredoxins are a family of proteins that protect cells from oxidative damage by
reactive oxygen species (ROS) and are also known as natural killer enhancing factors
(NKEF) because they can enhance natural killer cell cytotoxicity when presented against
tumor cells.90 In this assay, addition of fortilin to PRX1 increased its NADPH
consumption activity by 2.9 fold higher than PRX1 alone, while fortilin alone did not
increase NADPH activity. These data indicate that fortilin potentiates the activity of
PRX1, while not having endogenous peroxidase activity itself.
Additionally, fortilin was found to protect PRX1 from phosphorylation by
mammalian sterile twenty 1 (Mst1), a serine/threonine kinase, further potentiating PRX1
activity (Figure 1.8 A). When phosphorylated at its T90 and T183 residues by Mst1,
PRX1 becomes inactivated and is subsequently targeted for proteasomal degradation.91 In
an in vitro experiment, addition of Mst1 to PRX1 decreased NADPH consumption by
75.3%. When fortilin was present, PRX1 activity was rescued, such that only a 43.5%
decrease in NADPH consumption was observed. While the exact mechanism for Mst1
inhibition by fortilin has not been elucidated, computational predictions suggest that T90
and T183 residues of PRX1 dimers are physically blocked by fortilin from
phosphorylation by Mst1.89
1.2.3.b IRE1α Binding and Function
Endoplasmic reticulum (ER) stress sensors are proteins that are detached from the
ER membrane in response to oxidative stress as part of the unfolded protein response
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(UPR) in order to bind and sequester proteins that have been misfolded.92 One of these
proteins, inositol-requiring enzyme 1α (IRE1α), is ubiquitously expressed in mammals
and has been shown to bind fortilin both in vitro and in vivo in liver-fortilinoverexpressing mice.93 IRE1a is a multifunctional protein. On one hand, the kinase
domain, upon dissociation from GRP78, auto-transphosphorylates and then its RNase
domain splices X-box binding protein-1 (XBP1) mRNA to produce XBP1s, a
transcription factor that then translocates to the nucleus and initiates transcription of a set
of UPR-related genes.94 On the other hand, the kinase domain of IRE1α also activates the
Jun N-terminal (JNK) pro-apoptotic pathway by recruiting the scaffold protein TRAF2
and apoptosis signal-regulating kinase (ASK1), which then phosphorylates JNK and
activates the pathway.93 Fortilin was found to prevent ER stress from activating ERE1α
by preventing its protein kinase and RNase activities (Figure 1.8 B).93
1.2.3.c p53 Binding and Anti-Apoptotic Activity
Fortilin has a presence in the nucleus, the reason for which was unclear, and still
remains ambiguous.71 However, in 2011 it was determined that fortilin binds and inhibits
the function of the transcriptional regulator p53 and prevents transcriptional activation of
the pro-apoptotic protein Bax (Figure 1.8 C).95 In this study, fortilin was first found to be
co-localized with p53 in the nucleus, and not the nucleoli or cytosol, of U2OS cells
containing overexpressed hemagglutinin (HA)-tagged fortilin using both confocal
microscopy as well as co-immunoprecipitation assays. Additionally, it was determined
that both the N and C termini of fortilin were required for binding p53, as a glutathioneS-transferase (GST)-tagged fortilin was able to pull down p53 in co-immunoprecipitation
experiments when compared to GST alone or deletion mutants containing amino acids
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121-172. It was found that the domains containing the N terminus (amino acids 1-70) and
the C terminus (amino acids 121-172) could pull down p53, while the intermittent amino
acids (71-120) could not.95 These finding narrow the p53 putative binding site to near the
N and C termini of fortilin, independent of the presence of a GST affinity tag. However,
ideal conditions for binding studies require a cleaved GST tag from fortilin to ensure no
interference during binding. Computational docking done in the same study suggest that
fortilin blocks p53 binding to DNA by binding to the single-stranded DNA binding
domain (SSDBD) of p53.95 In vitro studies need to be done to elucidate the true binding
site of fortilin to p53.
1.2.3.d Calcium Scavenging
Calcium binding was first indicated in Trypanosoma brucei in 1992 and was
subsequently confirmed in various species.96–101 The mechanism by which calcium
scavenging by fortilin affects the cells was determined in 2007 (Figure 1.8 D).102
Fortilin was first confirmed to bind calcium by 45CaCl2 overlay assay, wherein proteins
separated by SDS-PAGE are then transferred to a PVDF membrane and treated with
45

CaCl2 and phosphor-imaged to detect 45Ca++. Next, 6his-fortilin was found to change its

secondary structure when in the presence of 10 mM Ca++ when analyzed via
spectropolarimetry. Once these in vitro studies were obtained, in vivo analysis both in
U2OS and MEF cell lines were performed. Utilizing thapsigargin, increased in Ca++
levels were induced, leading to Ca-induced apoptosis. siRNAfortilin transfection in U2OS
cells led to significant increase in intracellular Ca++ levels, indicating that the presence of
fortilin decreases overall Ca++ concentration in the cell. This experiment was repeated in
MEFfortilin+/- cells and compared to MEFfortilin+/+ cells (MEFfortilin-/- cells are not
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successfully isolated due to their lethal nature).103 In MEFfortilin+/- cells, the cellular
concentrations of fortilin are approximately one-half of that of MEFfortilin+/+ cells, and
when challenged by thapsigargin, MEFfortilin+/- cells exhibit higher levels of Ca++,
indicating that fortilin levels directly affect intracellular Ca++ levels and therefore exhibits
scavenging activity.
1.2.4 Known Functions of Fortilin: Cell Growth and Proliferation
1.2.4.a Tubulin Binding
GST-fortilin fusion protein has been demonstrated to bind both α and β-tubulin in
vitro (Figure 1.8 E).104 The experiments performed in this study were done against GST
controls to indicate that GST does not interfere with binding itself, however no study has
yet been done with fortilin with no fusion tag, which does not rule out completely the
possibility that an affinity tag may contribute to binding. Through the efforts of antibody
staining using a rabbit antipeptide antibody to localize fortilin and a mouse monoclonal
antibody against α-tubulin for microtubule staining, fortilin was found to be associated
with microtubules using confocal microscopy.104 In this study, fortilin levels were also
determined during different phases of cell cycle progression using fluorescent assisted
cell sorting (FACS) and found to be associated with microtubules during G1, S, G2 and M
phases, as well as being bound to the mitotic spindle during metaphase, leading to
dispatchment during the metaphase-anaphase transition. This study was among the
earliest to hint at a role for fortilin in cell cycle progression.
These findings were confirmed and expanded upon in 2009 when Bazile et al.
determined that TCTP aides in cell shape regulation by its interaction with both
microtubules and actin in both normal and cancer cells.105 In Xenopus XL2 cells,
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transfected fortilin containing a Myc tag was found to form along microtubules when
visualized by binding with a primary antibody (anti-c-myc) and secondary fluorescent
antibody fluorescein isothiocyanate and rhodamine-B isothiocyanate conjugated. Fortilin
was also observed in this manner to be colocalized in the mitotic spindle poles during
mitosis. However, microtubule dynamics were not affected by fortilin, as evident in an
assembly/disassembly assay performed with wild-type 6His-tagged fortilin and truncated
fortilin where a suspected binding domain sequence (amino acids 82-121), determined in
the previously mentioned study, were deleted and tested.104 The conclusion, here, is such
that while fortilin contains a sequence that binds putatively to microtubules, neither its
presence nor absence affects microtubule assembly or disassembly.
1.2.4.b Na/K-ATPase and EGFR
Fortilin was determined to prevent epidermal growth factor receptor (EGFR)
phosphorylation in HeLa cells upon inhibition of the Na+/K+-ATPase protein (Figure 1.8
F).106 Fortilin binds Na+/K+-ATPase within the third cytoplasmic domain to inhibit its
activity for maintaining cellular concentrations across the cellular membrane.107 EGFR
family proteins share a common ancestral backbone and are critical in cell growth,
development and homeostasis.108 A GFP-TCTP construct was found to induce EGFR
phosphorylation in HeLa cells in the same manner as EGF and Ouabain, a hypotension
drug.106 These findings, the authors claim, indicated that fortilin overexpression may
induce cell migration and that this, along with fortilin’s anti-apoptotic activity may
influence tumorigenesis.
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1.2.4.c Prevention of Alcohol-Induced Liver Damage via PRX1 Binding
There is evidence to suggest that over-expression of fortilin in certain cell types
may not always lead to a detrimental effect. When alcohol is consumed, the liver
metabolizes alcohol through alcohol dehydrogenase, the microsomal ethanol oxidizing
system, and aldehyde oxidase to produce ROS such as hydrogen peroxide.109 A role of
PRX1 is to convert hydrogen peroxide into hydrogen and water, thus protecting liver
cells from damage.110 One study done on liver-specific overexpression of fortilin in mice
found that PRX1 phosphorylation was reduced and PRX1 activity enhanced in mice
containing overexpressed liver fortilin when compared to fortilin-knockdown mice. 89
This activity prevented alcohol-induced liver damage when mice were administered with
10g/kg body weight of alcohol.89
1.2.4.d BMP Pathway and Embryo Survival
The bone morphogenic proteins (BMPs) bind serine/threonine kinase receptors,
known as BMP receptors, and are involved in signal transduction.111 In this study, the
overall goal was to develop a mouse line that was fortilin deficient (fortilin+/-) as well as
fortilin knockout (fortilin-/-). While fortilin+/- mice were found to be perfectly healthy and
able to reproduce, fortilin-/- embryos did not survive. These findings indicated the
possibility of an embryonic development role for fortilin, which was supported by qRTPCR and immunostaining on fortilin expression at the early developmental stages. RNAs
isolated from embryonic mice showed a peak in fortilin transcription at 9.5 days post
coitum (dpc), followed by a decrease over three days, and then back up to peak levels
between 16-18 dpc. Fortilin was determined to be an inhibitor of the BMP pathway in
Xenopus embryos, which share 68% homology with human fortilin (Figure 1.6). In this
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study, it was determined that fortilin inhibits the BMP-4 pathway in both Xenopus and
MEF cells by blocking BMP4 and blocks induction of Msx2, a pro-apoptotic protein,
thus leading to decreased apoptosis and subsequent embryo loss.103
1.2.5 Current research strategies for targeting fortilin in disease
1.2.5.a Known Small Molecule Binders of Fortilin and Characterized Binding
Sites
Ca2+

In 2007, the calcium binding site for human fortilin was determined via NMR
spectroscopy.79 In this study, small amounts of calcium chloride were titrated in to a 15N
labeled sample of 6His-tagged fortilin and the binding kinetics were measured as the
calcium concentration increased and peaks on the NMR spectrum, corresponding to
different amide groups in the peptide backbone of the protein, shifted. Based on this
study, which focused its efforts on the peak shift of Tyr132, a dissociation constant, or
Kd, was estimated to be between 22 and 25 mM. The putative binding site was
determined to be amongst amino acids Q133, N131, D150, L149, Y132 and Y151 with
oxygen atoms on Q133, N131 and D150, all located within the β-barrel, forming the
corresponding binding site and other residues shifting in response to calcium binding
(Figure 1.9).79 The binding constant determined here is not in conjunction with other
estimated binding constants determined by other groups, where a range from 8 to 10 mM
was previously determined.96,102 Feng et al. (2007) argue that for the 8 mM binding
constant that was previously determined, deletion experiments were used to determine the
Kd and thus this constant does not apply to natively folded fortilin.79 For the 10 mM
dissociation constant, a GST-tagged fortilin was used and thus we cannot rule out effects
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due to GST interference even though control experiments using GST alone were
performed.102 Experiments replicated by our lab using NMR spectroscopy and both GGSfortilin and fortilin-strep constructs have determined Kd values of 13 and 29 mM,
respectively, indicating that the presence of affinity tags and extra amino acids may
influence calcium binding.

Figure 1.9. Calcium binding to fortilin. Fortilin binds calcium wedged between
the β barrel and the α2 and α3 helices. Binding residues are shown as sticks and
labeled.
Dihydroartemisinin and Artemisinin

Dihydroartemisinin (DHA) and artemisinin are both drugs used in the treatment
of malaria (Figure 1.10). DHA was found to bind Plasmodium falciparum fortilin
containing a T7 peptide affinity tag in 1998 and then discovered to bind human GSTfortilin in 2008.112,113 While the DHA binding site has not yet been characterized, the
artemisinin site has been characterized in P. falciparum fortilin as of 2016.114 In this
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study, bioorthogonal click chemistry was used to determine the binding site, using heme
as an activator of artemisinin for binding with fortilin. The binding site for artemisinin is
closer to the N and C termini, which have been indicated as required sequences for
activity, and the amino acids within range include H181, Y175, E16, V7, K9, D15, T13
and N14 (Figure 1.10). It should be noted that the sequence for P. falciparum is slightly
different than that of human fortilin (see Figure 1.6).114 While the sequences for human
P. falciparum are slightly different, their structures are highly conserved and
computational predictions of binding done by our lab are found in the same location for
DHA as artemisinin.

Figure 1.10. Structures of DHA and artemisinin and binding to fortilin. Left –
structures of artemisinin and DHA. Right – Computationally predicted binding site
of both DHA and artemisinin using DHA as the SMI here. Residues proximal to
DHA within 3Å are shown. Computational prediction was done using AutoDock
Vina.22
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1.2.5.b Heart Disease: Rational Drug Design and Drug Discovery
Cardiovascular diseases (CVD) are the leading causes of death worldwide. These
include coronary heart disease, heart failure, stroke and hypertension and are prevalent in
approximately 48.0% of individuals aged 20 and older in the United States alone.115
Patients presenting with heart disease are commonly prescribed statin-based medications,
which are cholesterol-formation inhibiting drugs, in an effort to reduce low-density
lipoprotein (LDL) levels, wherein cholesterol is found. However, in a nationwide study
of lipid levels amongst patients hospitalized with CVD, approximately half of the
136,905 patients studied had LDL levels within the normal to low range.116 These
findings were further explored in 2017, when another hospital study concluded patients
presenting with atherosclerosis, where no previous risk factors were determined, these
patients had normal LDL-cholesterol levels. These findings highlight the need to develop
novel treatments for CVD that do not directly target cholesterol formation. Efforts are
currently underway to target fortilin for rational drug development in atherosclerosis.35,117
Fortilin was first proposed to be a viable target for drug development for
atherosclerosis in 2013 when pro-atherosclerotic, fortilin deficient, mice were found to
have ameliorated levels of atherosclerotic plaque and increased macrophage apoptosis.118
The overarching hypothesis is such that when fortilin function is inhibited, macrophage
apoptosis is propagated and less atherosclerotic plaques form (Figure 1.11).
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Figure 1.11. Fortilin potentiates foam cell formation. Fortilin prevents
macrophage apoptosis and propagates plaque formation. When inhibited,
macrophages may undergo normal apoptosis and prevent plaque formation.

1.3 NMR for Structural Characterization of Proteins and Rational Drug Design
1.3.1 Structural Determination of Proteins by NMR
In 1985, the first solution-state protein structure determined by NMR was
published by Williamson et al. for the proteinase inhibitor IIA from bull seminal
plasma.119 This new technique revolutionized structural elucidation of proteins because
until then, X-ray crystallography was the standard for structure determination. X-ray
crystallography requires the formation of protein crystals, whose generation can prove
quite trivial. Additionally, while SMI binding sites may be determined by X-ray,
dynamics studies are impossible. The development of protein techniques by NMR
spectroscopy allows for high resolution data that allows for dynamics studies for proteinligand interaction as well as dynamic structure elucidation in solution. The main
drawback to NMR over crystallography is such that proteins must be smaller in size, up
to 40-50 kDa, before analysis gets trivial because signals from too many molecules can
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be difficult to analyze. As for crystallography, if a protein can be crystallized, it can be
analyzed. Indeed, fortilin has been crystallized many times (Table 1.2).
In order to elucidate a three-dimensional protein structure, high concentrations of
isotopically labeled protein must be used, typically at a final concentration between 1-2
mM.120 To achieve a protein concentration of 1-2 mM for a protein the side of fortilin can
be fairly difficult logistically as isotopically labeled reagents such as 14NH4Cl and 13C
glucose are more expensive than their non-labeled counter parts. Isotopic labeling of
protein is a requirement for NMR spectroscopy because of atomic quantized spin. Atomic
nuclei containing odd mass or odd atomic number have the quantum mechanical property
of spin and can therefore be detected by NMR spectrometers.121 As proteins are
composed of amino acids and contain high levels of nitrogen, carbon and hydrogen,
isotopic enrichment is necessary for structure determination. For larger proteins than 50
kDa, 2H labeling of proteins may be necessary in order to suppress the proton signal to
elucidate structures. Reducing agents such as deuterated dithiothreitol (d-DTT) or tris(2carboxyethyl)phosphine (TCEP) hydrochloride are used to prevent dimer formation in
solution. Sodium phosphate buffers, as opposed to hydrogen phosphate buffers, are most
commonly used to prevent signal interference from unwanted protons, as well as an
optimized concentration of sodium chloride for protein stability. These conditions are
optimized for 3D determination of NMR solution structures.
Fortilin is an ideal candidate for NMR structure studies because it is relatively
small (approximately 19 kDa). For protein analysis by NMR, mg quantities of protein are
achieved by recombinant protein expression and purification techniques using E. coli
competent cell lines, or even yeast strains such as P. pastoris (Figure 1.12).120
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Figure 1.12. Protein preparation for NMR. Recombinant protein expression and
purification techniques are used to generate mg quantities of isotopically labeled
protein for analysis by NMR.
1.3.2 Binding Site Determination of SMIs to Protein by NMR
Protein-ligand interactions may be determined by NMR and is a commonly used
technique in structure based drug design (SBDD) for the rational development of drugs
for clinical use.122 Using NMR, binding sites on proteins that have been determined to be
potential targets are titrated with small molecules that bind specifically to the protein of
interest. This is done by taking 15N heteronuclear spin quantum coupling (HSQC) spectra
of the native protein, followed by adding in small amounts of SMI to determine which
peaks shift in response to increased amounts of small molecule. Binding isotherms are
used to determine binding constants, or Kd, values and the amino acids involved in
binding can be identified in this manner, called chemical shift mapping.123 We proposed
to use this technique with fortilin to known binders such as DHA and artemisinin to map
out binding sites of fortilin such that progress can be made in the rational drug design of
atherosclerosis drugs.
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1.4 Conclusions
Drug discovery is a long process that involves approximately 8-12 years and $3
billion. Drug repurposing provides a path by which researchers can use already clinically
tested and FDA approved drugs in order to find drugs that may treat a different disease
from the one the drug obtained approval to treat. In the realm of CVD and atherosclerosis
in particular, a critical need exists to develop novel drugs that target a mechanism other
than cholesterol formation, be they already approved drugs or novel. Fortilin is a
relatively novel protein that was first characterized in 2001 and is found to be involved in
myriad functions including anti-apoptotic, growth and proliferation. In atherosclerosis,
fortilin has been found to propagate arterial plaque formation by utilizing its antiapoptotic function to prevent macrophage apoptosis. The size of human fortilin,
approximately 19 kDa, makes it a good candidate for SBDD by NMR spectroscopy in a
rational drug design workflow. In order to study fortilin using this workflow, high
quantities of pure, isotopically labeled protein must be recombinantly expressed in an E.
coli competent cell expression system. The results of the work shown in this dissertation
provide the basis for expressing mg amounts of fortilin protein wherein an affinity
expression tag can be cleaved, and a construct can be generated without an affinity tag at
the N terminus. Studies performed via DSF and NMR spectroscopy with SMI’s are also
shown in this work.
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2.1 Introduction

Atherosclerosis, or the hardening and narrowing of arterial walls, is the leading
cause of death worldwide.124 Atherosclerogenesis occurs when low density lipoproteins
(LDL) in plasma diffuse into the intima of arteries and then become oxidized (oxLDL),
followed by uptake into macrophages. Macrophages eventually form foam cells, which
over time develop into plaques on the arteries, leading to blockages in blood flow that
cause cardiac events such as infarction, stroke, hypertension, etc. Presently, medications
used to treat atherosclerosis largely depend on inhibiting the formation of cholesterol in
vivo via the use of statins, which can cause undesirable side effects. For example, 3-

40
hydroxy-3-methyl-glutaryl-Co-A (HMG-CoA) reductase inhibitors (statin drug class) can
cause leg cramps in patients at night that lead to decreased compliance with treatment.125
Additional side effects may include cataracts and short-term memory loss.126 Moreover, a
recent study of 136,905 people showed that nearly half of all patients brought into the
emergency room with heart attacks had normal to low LDL levels in their blood.116 This
finding made evident the need to develop drugs that target other mechanisms in the
pathology of atherosclerosis than the in vivo formation of high cholesterol.
Fortilin is a promising drug target to treat atherosclerosis.35 Fortilin, also known
as translationally controlled tumor protein (TCTP), or histamine releasing factor (HRF),
is a highly conserved anti-apoptotic protein.127 Fortilin is a protein consisting of 172
amino acids that is found throughout the human body in the cytosol, nucleus, and
mitochondria of all cell types, blood and extracellular space.71,117 Fortilin exerts its antiapoptotic effect through multiple mechanisms; including calcium complexation and p53
inactivation, but it contributes to atherosclerosis by keeping macrophages in the M1 proinflammatory phenotype.35,128 Fortilin has been implicated in the progression of
atherosclerosis by reducing macrophage apoptosis by binding to and inhibiting p53, a
transcription factor that regulates the transcription of BAX, a pro-apoptotic protein. This
mechanism promotes foam cell formation, leading to deposits on arterial walls.128 Fortilin
also exhibits anti-apoptotic activity by scavenging free calcium in the cytoplasm of cells,
thus exerting a protective effect from calcium-induced apoptosis.102 Specifically,
inhibition of the pro-survival activity of could provide an orthogonal strategy to treat
atherosclerosis by shutting down the protective effects of fortilin.
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Fortilin is a 19 kDa protein that has 11 beta-strands and an extended flexible loop
between residues Tyr 39 and Val 66 (Figure 2.1a). The amino- and carboxy-termini are
in proximity to one another, creating a cavity that could be interrogated for small
molecule binding. The calcium binding site is coordinated by six oxygen atoms within
the beta barrel among residues H77, N131, Y132, Q133, and Y151 (Figure 2.1b).79
While a direct connection between fortilin, calcium scavenging, and atherosclerosis has
not yet been made, calcium-dependent apoptosis does occur during ox-LDL-induced
apoptosis and it is hypothesized that fortilin could play a role through its calcium
scavenging activity.129

Figure 2.1. Calcium-bound fortilin. A) Side view of fortilin (blue) bound to
calcium (magenta) with residues labeled for the flexible loop, the N- and C-termini,
and B) downward view of fortilin bound to calcium with complexed oxygen atoms
(red) shown and residues in proximity displayed as sticks. PDB structure 2HR9.
A structure-based approach to targeting fortilin will provide important
information for drug screening and defining drug binding sites. Structure-based drug
design (SBDD) is a technique commonly used to create small molecule therapeutics that
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specifically target a given protein.122,130 Solution nuclear magnetic resonance
spectroscopy (NMR) is an excellent tool for SBDD, for example, in screening small
molecule inhibitors (SMIs), mapping binding hot spots, and determining binding
affinities and kinetics.122 A solution structure of recombinant fortilin has been reported
using NMR.79 Feng et al., used a construct with a 6His affinity tag and required high salt
(200 mM) conditions for high quality NMR spectra.
NMR experiments require milligram quantities of pure, isotopically enriched and
bioactive protein. E. coli expression platforms are routinely used as they allow for
straightforward, high yield and affordable isotope enrichment.131 Ideally, an affinity tags
used in protein purification should be removed by enzymatic cleavage to ensure no
pseudo binding effects due to the presence of the affinity tag. The N- and C-termini of
fortilin form a beta strand that forms a pocket in the native structure. Affinity tags
attached at either the N- or C- terminus complicate the potential to target this site.
Functional studies of fortilin with an affinity tag are inconclusive due to the presence of
the affinity tag at the suspected small molecule binding site.113,114 Here, we describe the
design and assessment of several fortilin constructs for the purpose of expressing and
purifying a recombinant fortilin molecule with minimal non-native residues. Inclusion of
a short GGS linker between an HRV 3C protease cleavage site and the N-terminus of
fortilin resulted in milligram quantity of isotopically enriched 15N GGS-fortilin. Calcium
binding was observed by NMR titrations, demonstrating the structure and activity of this
construct were maintained. The work presented here shows that pure recombinant fortilin
can be proteolytically cleaved from an affinity tag and retain biological activity by the
insertion of a GGS linker sequence.
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2.2 Materials and Methods
2.2.1 Expression and Purification of S219V TEV Protease from E. coli
Recombinant TEV protease was expressed and purified using plasmid #8827 from
Addgene (pRK793) in BL21 (DE3) strain E. coli cells. From a glycerol stock, 20 mL of
LB containing 100 µg/ml ampicillin, 25 µg/ml chloramphenicol was inoculated, and
incubated overnight at 37 ºC with shaking at 200 rpm. This overnight culture was then
used to inoculate 1L LB containing 100 µg/ml ampicillin, 25 µg/ml chloramphenicol
with shaking at 37 ºC with 200 rpm. Once the OD600 reached between 0.5-0.7, a preinduction sample equivalent to 1 mL of cells at OD600 of 0.8 was collected, and the
culture flasks placed on ice and gently rotated every few minutes to cool the cultures. The
incubator was then set to 30 ºC and the cultures were reintroduced at the elevated
temperature and expression was induced with 1 mM IPTG, with shaking at 200 rpm. This
culture was incubated overnight. On the third day, a post-induction sample equivalent to
1 mL of cells at OD600 of 0.8. The pre- and post-induction samples were used to analyze
expression using SDS-PAGE. Lysis was halted by pouring the cultures into pre-weighed
500 mL centrifuge bottles and the cultures centrifuged at 6000 x g for 30 min at 4 ºC.
After centrifugation, the supernatants were removed, and the mass of the pelleted bacteria
weighed. The pellet was resuspended in 40 mL of lysis buffer consisting of 50 mM TrisCl pH 8.0, 300 mM NaCl, 20 mM imidazole, 10% (w/v) sorbitol, 20 mM 2mercaptoethanol, 0.02 mg/ml lysozyme, and 1X HALT protease inhibitors
(Thermofisher, USA). The suspension was sonicated on ice water at 60% power, 30 sec
on/30 sec off for 4.5 min of total pulse time and a 75 µl sample collected for SDS-PAGE
to check post sonication pellet and supernatant. The sonicated suspension was centrifuged
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at 16,000 x g for 30 min at 4 ºC. The supernatant was collected and filtered using a 0.45
µm PES filter. To the filtered lysate, 5 mL of Ni-NTA superflow slurry (Qiagen Cat
#30410/30430) was added and the mixture incubated overnight at 4 ºC with rocking. On
the fourth day, the lysate/resin mix was loaded into a column and the flow through
collected. Purification was carried out with a BioLogic LP System using EconoColumn
1.0 x 10 cm chromatography columns (Bio-Rad, Hercules, CA, USA). To line A, the
lysis buffer described previously was attached. To line B, the same lysis buffer with the
only difference being a 300 mM imidazole concentration was attached. Buffer A was run
over the column at a flow rate of 1.0 mL/min until the A280 stabilized, all while collecting
the flow through. The program for protein purification was as follows: Line A for 10 min,
Line B (0%-100% B, 1.0 mL/min) for 60 min, hold Line B for 10 min, and back to 100%
A for 10 min. Results were evaluated by SDS-PAGE. Fractions containing purified TEV
protease were combined, and protein concentration determined by absorbance at 280 nm.
Pooled fractions were diluted to a final concentration of 1 mg/ml in a 50% glycerol
solution, and 0.5 mL aliquots stored at -80 ºC.
2.2.2 Expression Plasmid Constructs
The fortilin-StrepTag II construct plasmid was purchased from IBA Lifesciences
in the pASG-IBA3 expression vector (Göttingen, Germany). All other plasmids were
purchased from ATUM (Newark, CA) using their pD441-SR vector. These constructs
consisted of glutathione S-transferase (GST), maltose binding protein (MBP), and 6histidine (6His) affinity tags, human rhinovirus (HRV) 3C and tobacco etch virus (TEV)
protease recognition sites, and glycine-glycine-serine (GGS) linkers of varying length
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(GGS)N where N = 0, 1, 2 or 3 at the N-terminus of fortilin in the pD441-SR expression
vector.
2.2.3 Expression of Recombinant Fusion Proteins
Plasmids were transformed into 50 µL of competent E. coli cells using the heatshock method at 42 °C. Single colonies were inoculated into 5 mL of Luria-Bertoani
(LB) medium containing 50 μg/mL kanamycin and grown at 37 °C overnight with
shaking at 250 rpm. One mL of each overnight culture was inoculated into 100 mL LB
medium containing 50 μg/mL kanamycin and grown at 37 °C with shaking at 250 rpm
until the OD600 reached between 0.60 and 0.80. Once reached, IPTG was added to 0.1
mM to induce protein expression. Expression continued at these conditions for 6 h.
Expression was halted by centrifugation at 4,000 x g for 20 min and expression analyzed
by SDS-PAGE on 12% bis-acrylamide gels.
2.2.4 Expression of 15N-labeled Recombinant Fusion Proteins for NMR Spectroscopy
Plasmids were transformed into 50 µL of competent E. coli cells using the heatshock method at 42 °C. Single colonies were inoculated into 5 mL of LB medium
containing 50 μg/mL kanamycin and grown at 37 °C and grown for approximately 8
hours. One mL of each culture was inoculated into 50 mL of M9 minimal media
containing 50 μg/mL kanamycin and grown at 37 °C overnight.
2.2.5 Cell Lysis
Cell pellets (approximately 0.13 g each) from 100 mL cultures were resuspended
in 2 mL lysis buffer containing 150 mM NaCl, 50 mM tris-HCl pH 7.8, 1 mM EDTA and
0.1% Triton X-100. Lysozyme was added to a final concentration of 0.25 mg/ml as well
as ½ tablet of HALT protease inhibitor cocktail (Pierce, Rockford, IL). The lysate was
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then subjected to sonication at 70 % power for 30 sec on/ 30 sec off for a total of two
minutes. Samples were then centrifuged at 17,000 x g for 45 min at 4 °C. The resulting
lysate was filtered through a 0.45 μm cellulose acetate filter and subjected to affinity
purification.
2.2.6 Purification of GST-3C-(GGS)N-Fortilin and GST-3C-TEV-Fortilin from
BL21(DE3) Cells
GSTrap sepharose 4B 1 mL pre-packed columns were used for purification (GE
Healthcare, Marlborough, MA). Separate columns were used for each linker sequence to
avoid contamination of samples. Samples were loaded onto the column with a flow rate
of 1.0 mL/min and washed with 1X phosphate buffered saline (PBS) with a flow rate of
1.0 mL/min for 20 mL, followed by a 10 mL elution with GSTrap elution buffer
containing 50 mM Tris-HCl pH 8.0 and 10 mM reduced glutathione. Elution was
followed by a 10 mL wash at 1.0 mL/min with 1X PBS (Appendix A. Figs 1-3 and 5).
All solutions used for affinity chromatography were filtered through 0.22 μm nylon
filters and degassed under vacuum with rigorous stirring for at least one hour.
2.2.7 Purification of 6His-MBP-10N-3C-TEV-Fortilin and MBP-TEV-Fortilin
Amylose resin (New England Biolabs, Ipswich, MA) was used for purification of
MBP-tagged proteins. An approximately 50% slurry of affinity beads to 20% ethanol
were used to pack a column by gravity until the column volume reached 3 ml. The
column was equilibrated with 25 mL of column buffer containing 20 mM Tris-HCl pH
7.4, 0.2 M NaCl and 1 mM EDTA. The clarified lysate was added to the column and the
flow through collected. This step was repeated once to improve protein binding. Next, the
column was washed with 10 column volumes (CV) of the column buffer described above.
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This was followed by elution by flowing 5 CV of column buffer containing 10 mM
maltose, collected over three elution steps. A final wash step of 10 CV column buffer was
performed to remove any remaining protein (Appendix A. Figs. 4 and 6).
2.2.8 Purification of 6His-TEV-Fortilin
Nickel agarose resin (HisPurTM Ni-NTA Superflow agarose, Thermofisher, USA)
was used for purification of 6His-TEV-fortilin. An approximately 50% slurry of affinity
beads to 20% ethanol we used to pack a column by gravity until the column volume
reached 3 ml. The column was equilibrated with 25 mL of buffer containing 50 mM TrisCl pH 8.0, 300 mM NaCl, 20 mM imidazole. Next, the clarified lysate was added to the
column and the flow through collected. This step was repeated once to improve binding
to the column. The column was then washed with 10 CV of buffer containing 50 mM
Tris-Cl pH 8.0, 300 mM NaCl, 20 mM imidazole. This was followed by elution with 5
CV of buffer containing 50 mM Tris-Cl pH 8.0, 300 mM NaCl, 200 mM imidazole
(Appendix A. Fig. 5).
2.2.9 Cleavage of Affinity Tags from Fusion Proteins and Removal of Proteases
Samples containing purified fusion protein underwent cleavage with either human
rhinovirus 3C (HRV 3C) protease and/or tobacco enterovirus (TEV) protease using the
Pierce HRV 3C protease solution kit (Pierce, Rockford, IL) according to manufacture
protocols, as well as an in-house grown TEV protease using 2 μL protease solution for
every 200 μg of protein. Protease removal was also done according to manufacture
protocols by purification over glutathione agarose or sepharose beads or HisPur Ni-NTA
Superflow Agarose (Thermo Scientific, Waltham, MA). The cleaved protein was
separated by size exclusion chromatography using an S75 column equilibrated withinto
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100 mM NH4HCO3 (GE Healthcare, USA). Fractions containing pure protein were
combined and concentrated using 5 MWCO PES Vivaspin 20 columns (Sartorious,
Stonehouse, UK) by centrifugation at 4000 x g until the volume reached approximately
10 mL. These were then aliquoted such that microcentrifuge tubes contained 2 mg protein
each and lyophilized at 2 atm and -80 °C overnight using a LabConco FreeZone 2.5 Plus
lyophilizer (LabConco, Kansas City, MO, USA). Samples were stored at -20 °C.
2.2.10 SDS-PAGE Analysis of Protein Expression, Purification and Cleavage
Protein expression, purification and cleavage steps were analyzed using sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Samples were prepared
such that equal loading was observed in each gel. Gels (12%) resolving and stacking
(6%) gels were made according to standard protocol and used for protein separation.
Quantification was done using GelAnalyzer 19.1.132
2.2.11 NMR Spectroscopy for Activity Assay via Calcium Titration of (GGS)N-Fortilin
Lyophilized (GGS)N-fortilin (1.76 mg) was resuspended in 500 μL of a 20 mM
tris-Cl buffer, pH 8.0, containing 200 mM NaCl and 10% D2O. An aqueous 1 M CaCl2
stock solution was used for each titration. All experiments were performed at 308 K on a
600 MHz Bruker Ultrashield NMR spectrometer equipped with a cryoprobe. For each
titrant, 1-2 μL stock CaCl2 was added to a microcentrifuge test tube containing the NMR
sample. This was then placed into a glass NMR tube, with care taken to avoid air
bubbles. This was then placed in the NMR spectrometer and measurements taken. Data
analysis was done using ccpNMR Analysis V3.133,134
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2.2.12 LC-MS Based Proteomics Analysis
Proteomic analysis was performed using a method established previously with
modifications.135 Excised gel pieces were destained in 50 mM ammonium
bicarbonate/50% acetonitrile, reduced in 10 mM DTT for 60 min at 56 oC, and alkylated
in 55 mM iodoacetamide for 60 min at room temperature in the dark. Gel pieces were
then digested with proteomics grade trypsin (Thermo Fisher Scientific, Waltham, MA,
USA) overnight at 37 ºC. Resulting peptide mixtures were chromatographically separated
on a reverse-phase C18 column (10 cm x 75 µm, 3 µm, 120 Å) and analyzed on a Velos
Pro Dual-Pressure Linear Ion Trap mass spectrometer (Thermo Fisher Scientific) as
described previously.135
Peptide spectral matching and protein identification were achieved by database
search using Sequest HT algorithms in Proteome Discoverer 2.2 (Thermo Fisher
Scientific). Raw spectrum data were searched against a protein sequence database
containing the anticipated sequences and UniProtKB/Swiss-Prot protein database for E.
coli (acquired from www.uniprot.org on November 3, 2020). Main search parameters
included: trypsin, maximum missed cleavage site of two, precursor mass tolerance of 1.5
Da, fragment mass tolerance of 0.8 Da, fixed modification of cysteine
carbamidomethylation (+57.021 Da), and variable modification of methionine oxidation
(+15.995 Da). Decoy database search was performed to calculate false discovery rate
(FDR). Proteins containing one or more peptides with FDR≤0.01were considered
positively identified and reported.
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2.2.13 Statistical Analysis
Statistical analysis was carried out using IBM SPSS Statistics 26 for Windows
(IBM Corp., Armonk, NY) Statistical significance of differences between groups was
evaluating using one-way analysis of variance (ANOVA), and Bonferroni post-hoc test
used to assess the significance of differences between individual groups. Values of p <
0.05 were considered to be statistically significant. Data are presented as ± standard
deviation (SD).
2.2.14 Figure Generation
Figures were made using GraphPad Prism v. 8 (GraphPad, San Diego, CA),
Inkscape v. 0.92 (Free Software Foundation, Boston, MA) as well as Adobe Illustrator v.
24.1 (Adobe Inc., San Jose, CA).
2.3 Results
2.3.1 Expression and Purification of Recombinant Human Fortilin.

Figure 2.2. Constructs used for recombinant fortilin expression, purification, and
cleavage. All constructs were made in ATUM’s pD441-SR vector.
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Initial efforts to produce a tag-less version of fortilin were hindered by an
inability to remove affinity tags by enzymatic cleavage. TEV protease cleavage sites
were designed adjacent and N-terminal to fortilin in constructs that included a 6His, a
maltose binding protein (MBP), and a dual tagged 6His-MBP tag (Figure 2.2). The 6HisTEV-fortilin, MBP-TEV-fortilin and the 6His-MBP-10N-3C-TEV-fortilin constructs
were all resistant to TEV protease after 48 hours incubation at room temperature
(Figures 2.3 and 2.4). The activity of the TEV protease was confirmed on an in-house
construct that is identical to the MBP-TEV-fortilin except that is contains the oncostatin
M gene (MBP-TEV-OSM) (Figure 2.3; Lane 2).
It is well-documented that affinity tags can introduce steric hinderance, making
the enzymatic cleavage less efficient, although this does not explain the resistance of the
6His-TEV-fortilin construct. Further, the 6His-MBP-10N-3C-TEV-fortilin construct has
an additional Human 3C rhinovirus protease cleavage site N-terminal to the TEV
cleavage site. Treatment of the 6His-MBP-10N-3C-TEV-fortilin with 3C protease after
24 hours at 4 ºC resulted in 72% cleaved fortilin, albeit with an additional remaining 3C
(Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro) and TEV (Glu-Asn-Leu-Tyr-Phe-Gln-Gly-Ser)
amino acids; with no additional cleavage observed after 48 hours. These observations led
us to hypothesize that for efficient cleavage, a linker was needed between the protease
cleave site and the fortilin protein.
Incorporating a GGS linker between the protease cleavage site and fortilin
increases enzymatic protease cleavage efficiency by increasing the space between the
protein and cleavage site. Here, we chose to incorporate GGS linkers between the
protease cleavage site and the N-terminus of fortilin. We chose the repeating GGS motif

52
because of the flexibility, experimentally determined random coil behavior, and charge
neutrality.136,137 GGS linker units were either not included in the construct (GGS)0 or
included in increasing repeats of GGS from (GGS)1 to (GGS)3. Addition of just one GGS
linker to the N-terminus of fortilin was sufficient to produce a successfully cleaved
construct, with approximately 86.5% recovered GGS-fortilin after cleavage with 3C
protease (Table 2.1). Addition of two GGS linker sequences provided 81.5% recovery of
(GGS)2-fortilin, and addition of three GGS linkers provided for 85% recovery.
Confirmation of cleavage reactions was analyzed by SDS-PAGE (Figure 2.5) and
compared to a positive control of GST-3C-Syk protein (included in the Pierce Protease
kit) to ensure protease efficacy. All samples were also compared against negative
controls wherein no protease was added. While addition of extra (GGS)N linkers provided
equivalent recovery of (GGS)N-fortilin, we decided that just one GGS linker would be
sufficient for NMR studies as well as reduce the effects of potential steric hindrance from
more than one GGS linker sequence at the N terminus. Addition of one GGS linker
sequence at the N-terminus of fortilin provides sufficient access for a protease to cleave
an affinity tag from fortilin for biological studies.
All constructs produced soluble and good quantities of fortilin; recovery yields
are available in Table 2.1. Yields were quantified in comparison to the respective noncleaved construct on the same SDS gel.
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Table 2.1.
Percent yield of tag free fortilin after one day to cleave constructs.
Yields quantified using SDS PAGE image analysis using GelAnalyzer.
Construct

Cleaved construct

6His-TEV-fortilin
6His-MBP-10N-3C-TEVfortilin
GST-3C-TEV-fortilin
GST-3C-(GGS)0-fortilin
GST-3C-(GGS)1-fortilin
GST-3C-(GGS)2-fortilin
GST-3C-(GGS)3-fortilin

fortilin
TEV-fortilin

Percent (%) recovery of
cleaved fortilin
0
72

TEV-fortilin
fortilin
GGS-fortilin
(GGS)2-fortilin
(GGS)3-fortilin

28
<1
87
82
85

2.3.2 Cleavage MBP Constructs Provided Insight for How to Successfully Cleave an
Affinity Tag from Fortilin.
MBP-TEV-fortilin was cleaved by TEV protease after 48 hours incubation at
room temperature. Uncleaved MBP-TEV-fortilin can be seen to appear at approximately
62 kDa on an SDS-PAGE gel (Figure 2.3). A dark band at 42 kDa indicates the MBP
affinity tag, which was expressed in conjunction with the MBP-TEV-fortilin construct.
For the 6His-MBP-10N-3C-TEV-fortilin construct, cleavage was observed upon addition
of HRV 3C protease after one day, with no additional cleavage after two days. No
cleavage was observed for this construct upon addition of TEV protease. In Figure 2.3,
arrows indicate cleaved TEV-fortilin after one and two days, respectively. No additional
cleavage was observed after two days of cleavage reaction, indicating that just one day is
required for cleavage to be successful. Both constructs were run against a house-made
positive control of MBP-TEV-OSM, or Oncostatin M, a construct known to cleave
successfully upon addition of TEV protease.138 A positive control for HRV 3C protease is
shown in Figure 2.5, where the GST-Syk protein has been successfully cleaved,
demonstrating that both proteases were active at the time of use.
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Figure 2.3. MBP construct cleavage reactions. SDS-PAGE gel of TEV and 3C
protease cleavage reactions. Cleavage reactions of MBP constructs against a positive
control lane of MBP-TEV-OSM. Uncleaved MBP-TEV-fortilin can be seen to
appear at approximately 62 kDa on an SDS-PAGE gel. A band at 42 kDa indicates
the MBP affinity tag, presumably due to abortive translations for the MBP-TEVfortilin construct. Arrows indicate successfully cleaved TEV-fortilin.
2.3.3 GST Affinity Tags Were Cleaved With 3C Protease While 6His-TEV Cleavage
Was Unsuccessful.
The GST-3C-TEV-fortilin construct showed no cleavage after two days of
incubation with TEV protease (day 2 data not shown). However, upon incubation with
HRV 3C protease, cleavage was observed after just one day. TEV-fortilin is indicated by
an arrow in Figure 2.4. As for the 6His-TEV-fortilin construct, no cleavage was observed
upon addition of TEV protease after two days of incubation at room temperature. The
6His-TEV-fortilin band was confirmed by mass spectrometry, demonstrating that
cleavage had not occurred. The positive control band in Figure 2.4 is MBP-TEV-OSM,
which showed that the TEV protease was active. The positive control for HRV 3C
indicates that the 3C protease is active when used against the GST-3C-Syk (Figure 2.5).
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Figure 2.4. Protease cleavage sites located proximal to the N-terminus are
resistant to cleavage. Cleavage reactions of GST and 6His constructs against a
positive control lane of MBP-TEV-OSM. Protein ladder is shown in the first lane to
indicate molecular weight markers on a 12% bis-acrylamide gradient SDS gel. The
arrow indicates successfully cleaved TEV-fortilin, where the 3C cleavage site is Nterminal to the TEV protease cleavage site.
2.3.4 Insertion of (GGS)N Linkers Allow for Affinity Tag Cleavage.
Because the previous constructs containing TEV sequences between the 3C
sequence and the fortilin sequence showed successful cleavage, we investigated whether
a glycine-glycine-serine (GGS) linker repetition sequence would also result in successful
cleavage at the N-terminus and yield intact protein. We used (GGS)N linker sequences
where N = 0, 1, 2 or 3 (see Figure 2.5). The positive control lane consists of GST-3CSyk, which was used to show protease activity. We found that the inclusion of just one
GGS linker sequence (GGS)1 led to cleaved fortilin with the sequence GGS-fortilin; this
result was verified against a negative control of (GGS)0, as well as no addition of HRV
3C protease. While additional linker sequences proved successful, we moved forward
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with (GGS)1-fortilin for NMR analysis to minimize N-terminal binding interference by
tag amino acids.

Figure 2.5. Cleavage reactions of (GGS)N constructs. N = 0, 1, 2 or 3 against a
positive control lane of cleaved GST-3C-Syk. Protein ladder is shown in the first
lane to indicate molecular weight markers on a 12% polyacrylamide SDS gel.
Arrows indicate successfully cleaved (GGS)N-fortilin that was confirmed by mass
spectrometry.
2.3.5 Biological Activity of Fortilin.
2.4.5.a Calcium Titration of (GGS)1-Fortilin.
a 1 M aqueous solution of calcium chloride (CaCl2 ) was titrated into a solution of
176 mM (GGS)1-fortilin. Aliquots of 1 µL CaCl2 were used for each titration point for a
total of 6 points. Notable peak shifts in the titration can be seen in Figure 2.6 where
arrows indicate increasing concentrations of CaCl2 . The combined chemical shifts were
calculated for peaks with large shifts (list them here) were used to calculate Kd values
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using the binding isotherm:
Kd of 14.2 ± 3.7 mM.

𝐾𝐾𝑑𝑑+𝐿𝐿+𝑅𝑅−�(𝐾𝐾𝐾𝐾+𝐿𝐿+𝑅𝑅)2 −4𝑅𝑅𝑅𝑅
2𝑅𝑅

∗ 𝐵𝐵𝑚𝑚𝑚𝑚𝑚𝑚. We determined a binding

Figure 2.6. 1H,15N HSQC spectral overlay of GGS-fortilin titrated with calcium.
Y132, Y151, N131, Q133, and H77 are labeled with arrows indicating increasing
concentrations of calcium.
2.4 Discussion
The successful cleavage of the 6His-MBP-10N-3C-TEV-fortilin and GST-3CTEV-fortilin constructs led us to the hypothesis that, at the N-terminus, space is required
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for a protease searching for a cleavage recognition sequence to gain access to the
cleavage site. Insertion of just one GGS linker sequence, at the N-terminus and before the
cleavage site, provided 78% recovery of GGS-fortilin (Figure 2.5). Further
characterization of this activity needs to be done to determine the mechanism by which
native fortilin hinders protease activity at the N-terminus. According to computational
ligand docking studies performed by our lab that were consistent with a previous study,
the N-terminus is a predicted location for small molecule binders and is required for
activity.93,139 Additionally, the N-terminus has been shown to be highly conserved among
various species and is required for fortilin’s anti-apoptotic activity both in vivo and in
vitro when binding to Bcl-xL, a protein that is required in cell survival maintenance.139
This is experimentally backed by previous work published using Plasmodium falciparum,
where the artemisinin binding site was characterized, and the binding site was near the Nterminus.114 Indeed, previous computational work published by our lab has shown that
fortilin binds peroxiredoxin-1 (PRX-1), a protein implicated in reactive oxygen species
(ROS)-mediated apoptosis, near the N-terminus.89 It should be noted, however, that to
date the binding site for artemisinin to human fortilin has not been characterized in
human fortilin, while evidence suggests that dihydroartemisinin (DHA) does bind human
fortilin.113,114
It is well established that fortilin binds to calcium and the binding site has been
characterized (see Figure 2.1).79,98,101 For the present study, we reproduced CaCl2
titration analysis with the 15N-labeled (GGS)1-fortilin protein using NMR spectroscopy
and obtained a Kd value of 14.2 μM, which is within reason to previously reported Kd’s
for Ca2+.79 Multiple literature reports provide the Kd values for calcium binding to fortilin
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at 7.58 μM, 17.5 μM, 22 mM and 25 mM.79,96,102 The present study shows that
recombinant fortilin, in the absence of an affinity tag, still binds calcium. Biologically,
fortilin binds calcium to mediate histamine release from basophils, which play a critical
role in immune system function.127
2.5 Conclusions
The present study has shown that recombinant, pure, isotopically labeled fortilin
can be produced with a cleavable affinity tag when just one GGS linker is added to the Nterminus. This indicates that the N-terminus is partially hidden from protease in the
absence of the linker sequence. More studies need to be performed to not only determine
the mechanism by which addition of a GGS sequence facilitates cleavage, but to also
characterize the interaction of small molecules at the N-terminus, such as artemisinin and
DHA, which bind but have not been characterized in human recombinant fortilin.113,114
Additionally, NMR studies need to be performed on fortilin in other expression systems,
such as yeast, to explore the possibility of post-translational modifications (PTMs), and to
determine the differences in binding between recombinant fortilin products in E. coli, P.
pastoris, and human cell lines.
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CHAPTER THREE: STRUCTURE AND TITRATION STUDIES OF NOVEL
FORTILIN CONSTRUCTS WITH AFFINITY TAGS WITHIN THE FLEXIBLE LOOP
Manuscript in preparation
Maranda S. Cantrell1, Aaron D. Ajeti1, Ken Fujise2, Owen M. McDougal1, Lisa R.
Warner1
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3.1 Introduction

Cardiovascular diseases (CVDs) such as atherosclerosis are a significant global
health issue.115 According to the Center of Disease Control, cardiovascular disease ranks
number one for mortality rates in the United States with an average morbidity rate of
659,041 deaths per year.140 CVDs also account for an average of 110 billion dollars in
expenditures for diagnoses and treatments with the average cost per year trending
upward.141 Other projections for CVD include 45.1% of the US population having some
form of CVD by the year 2035.142 The combined need to lower mortality rates, disease
prevalence, and health expenditures requires a drastic acceleration of our efforts to
combat CVDs, especially atherosclerosis.
The current treatments for atherosclerosis work to lower cholesterol production
and levels in the blood.115 Unfortunately, these treatments are insufficient as
atherosclerosis is dependent on the formation of foam cells that form from circulating
macrophages, as opposed to high levels of cholesterol.115,143,144 The formation of foam

61
cells is initiated when circulating monocytes take up oxidized low density lipoproteins
(oxLDL) and differentiate into macrophages.143 Typically oxLDLs will trigger cellular
apoptosis, but if that mechanism is inhibited, the macrophages will continue to
phagocytize oxLDLs and form foam cells.143 These foam cells are then allowed to deposit
on the walls of arteries and form plaques, promoting atherosclerosis. Over time,
blockages may form and lead to cardiac events such as heart attack and stroke.
In 2013, mouse studies were performed to determine whether the protein fortilin
promoted the progression of atherosclerosis.118 In this study, the gene to express LDL
receptor (LDLR) was knocked down (LDLR-/-) in order to form a mouse model of
atherosclerosis formation.118 These mice were then crossbred with mice that had one
copy of the fortilin gene knocked down (fortilin +/-). This cross breeding generated mice
that were fortilin+/- LDLR-/- and fortilin+/+ LDLR-/-.118 It was discovered that mice with the
heterozygous expression of fortilin upregulates the mechanism of apoptosis of
macrophages and hinders the development of plaques.118 These mouse models provided
strong evidence that fortilin was a potential target for drugs to treat atherosclerosis.
Fortilin is a 172 amino acid, 19 kDa polypeptide comprised of two α-helices, a
nine strand β-barrel, and a large flexible loop (Figure 3.1).145 A point of interest for
rational drug design of inhibitors of fortilin is the close proximity of the amine (N)
terminus and the carboxylic (C) terminus that may function as the ligand binding
domain.145 In order to determine drug candidates that will target and inhibit the
indigenous function of fortilin, a structure-based approach has been initiated.
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Figure 3.1. Structural characteristics of fortilin. The secondary structures
contained within fortilin include two α-helices, one nine-strand β-barrel, and one
flexible loop. Another structural quality of interest is the neighboring N- and Ctermini. Strand β9 and Loop Lα3β8 contain the coordination sites for Ca2+ binding.
Nuclear magnetic resonance (NMR) spectroscopy is a common method to
elucidate the structure of macromolecules and potential binding sites with other
molecules.146–149 Heteronuclear single quantum coherence spectroscopy (HSQC),
provides a “fingerprint” spectrum of proteins where each peak correlate to either an
amide in the backbone or a side chain amine in the protein. Although NMR has proven to
be a powerful tool to advance drug discovery, it is important to note that there are
limitations to NMR.148 NMR is a relatively insensitive technique that requires milligram
quantities of isotopically enriched protein to perform a structural or dynamic study.148
The Escherichia coli (E. coli) expression system has previously been successful in
expressing the necessary amounts of recombinant fortilin.150 High purity fortilin has been
successfully attained using a nickel affinity column and 6-histidine (6His) affinity tail
fused to fortilin at the N terminus.79 NMR structure models have been reported for
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fortilin, as well as Ca2+ affinity evidenced by side chain proton chemical shifts correlated
to Ca2+ titration, observed by 1H/13C HSQC NMR studies.79 However, to date,
recombinant fortilin protein has not been purified in the absence of an affinity tag
attached at either the N- or C-terminus.
Affinity chromatography is a widely used technique in protein purification to
simplify the overall purification process.151 The affinity tag is placed on a protein for it
to bind to an affinity column, permitting all of the other water-soluble proteins to be
washed away. The affinity tagged protein can then be eluted from the column by addition
of a competitive binder of the column solid support, resulting in the displacement of the
protein of interest. In the primary sequence of a protein, the affinity tag, typically located
at the N-terminus, is followed by a protease cleavage sequence i.e., tobacco etch virus
(TEV) protease (ENLYFQ) or human rhinovirus 3C (HRV 3C) protease (LEVLFQ),
before the protein sequence begins. The protease cleavage sequence allows for
proteolytic cleavage of the affinity tag such that no amino acids are left behind at the Nterminus. Previous work done by our lab showed that addition of a GGS amino acid
linker sequence at the N-terminus of fortilin could be successfully cleaved and Ca2+
affinity conserved.150 However, we were unable to remove the GGS tag from the Nterminus which provides uncertainty regarding the ability of inhibitors bind at the
computationally predicted, N-terminus, ligand binding site.89,93
There is a growing precedent for placing affinity tags within non-structured
locations of proteins for purification purposes as well as activity studies, specifically with
FLAG and myc antibody affinity tags.152,153 However, for NMR studies, milligram
quantities are required, whereas antibody chromatography is typically performed in
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smaller amounts due to the increased cost. To address this, we designed three different
constructs (NSer46, CSer46 and CGly56) of fortilin, with the strep-tag affinity sequence
(WSHPQFEK) inserted inside of the flexible loop at different locations (Figure 3.2). The
loop constructs were designed to eliminate the need for protease cleavage and removed
non-native residues at the N and C termini of fortilin. We performed CD and NMR
analysis to determine whether the overall structure of fortilin was greatly altered by the
introduction of mutants and performed Ca2+ titrations using NMR spectroscopy to
determine if Ca2+ binding affinity was conserved.

Figure 3.2. A block diagram showing the locations of the eight-residue strep
affinity tag (green) within the flexible loop (blue). Top: shows a location of the
affinity tag on amide end of Ser46. Middle: shows a location of the affinity tag on
the carboxy end of Ser46. Bottom: shows the location of the affinity tag on the
carboxy end of Gly56. The integrity of the structures of the mutant constructs were
determined by NMR studies and compared to that of wild type fortilin (PDB 2HR9).
Ca2+ titrations were then performed to assess retention of Ca2+ affinity.

3.2 Materials and Methods
3.2.1 Plasmids
All plasmids used in this study for the loop constructs were purchased from
ATUM (Newark, CA, USA) using their pD441-SR expression vector. The wild-type
fortilin-strep construct was purchased from IBA Lifesciences (Göttingen, Germany)
using their pASG-IBA3 expression vector.
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3.2.2 Bacterial Cell Transformation and Cell Stock Preparation
For transformation, 1-5 µL of plasmid DNA was added to 50 µL of competent
BL21(DE3) E. coli cells and incubated on ice for 20 min. Cells were then heat shocked
by incubating at 42 °C for 45 seconds, followed by incubation on ice for 2 min. To this,
500 µL of LB broth was added and the solution incubated with shaking at 225 rpm at 37
°C for 45 min. Two LB agar plates containing 25 mg/ml kanamycin were used for
plating, with 50 µL spread on one plate and 450 µL spread on the second plate using a
turn table and L-shaped spreader. These plates were incubated upside down at 37 °C
overnight. For cell stocks, a swipe of colonies was added to 5 mL of LB containing either
25 µg/ml kanamycin (for loops constructs) or 50 µg/ml ampicillin (for fortilin-strep) and
incubated at 37 °C for 6-8 hours with shaking at 225 rpm. A sterile 50% aqueous glycerol
solution was used to add 500 µL of glycerol to 500 µL of the cell culture. This mixture
was flash frozen in liquid nitrogen and stored at -80 °C.
3.2.3 Protein Expression.
Expression was generated from plated cells on LB agar containing either 25
µg/ml kanamycin (for loop constructs) or 50 µg/ml ampicillin (for fortilin-strep) either
from 50% glycerol cell stocks or from bacterial cell transformation of plasmids. Multiple
colonies from a LB agar plate were inoculated into 5 mL of LB containing either
kanamycin or ampicillin and incubated at 37 °C with shaking at 225 rpm for 6-8 hours.
The culture was then centrifuged at 4000 x g for 10 min at 30 °C and the media
discarded. The pellet was resuspended in 50 ml of pre-warmed M9 minimal media
containing appropriate antibiotic in a 250 mL Erlenmeyer flask and incubated overnight
at 37 °C. The next morning, this culture was transferred to a 50 mL conical tube and
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centrifuged at 30 °C for 10 min, and the media discarded. The pellet was resuspended in
1 L of pre-warmed M9 minimal media containing antibiotic and 15N-NH4Cl as the sole
nitrogen source and 0.5 g/L 15N isogro (Thermofisher, USA). This culture was incubated
at 37 °C with shaking at 225 rpm until the OD600 reached 0.5-0.7 (about 2 hours) and
either IPTG (for the loop constructs) added to a final concentration of 1 mM or
anhydrotetracycline (for the fortilin-strep construct) to a final concentration of 0.2 µg/ml
to induce protein expression, and the temperature lowered to either 30 °C for 6-hour
expression, or to 18 °C for overnight expression. Expression was halted by centrifugation
at 4000 x g for 20 min at 4 °C. Pellets from 1 L cultures were resuspended in 40 mL lysis
buffer containing 100 mM Tris-Cl pH 8.0, 150 mM NaCl, 1 mM EDTA as well as 0.1
mg/ml chicken egg white lysozyme (FisherSci, USA), 1 crushed tablet of Pierce protease
inhibitor cocktail (Thermofisher, USA) and 1 µL of DNase (Thermofisher, USA). This
solution was stored at -20 °C until purification for up to 2 weeks.
3.2.4 Cell Lysis.
Lysis solutions were thawed in a room temperature water bath until no ice
remained (approximately 30 min). Lysis was obtained by sonication at 70% amp for 3
minutes of total sonication (6 cycles of 30 sec on, 30 sec off). During sonication, samples
were kept on ice containing NaCl to keep the samples as cold as possible during this
process. After sonication, samples were centrifuged at 20,000 x g for 45 min at 4 °C. The
supernatant was collected and filtered through at 0.45 µM PES syringe filter (Fisher,
USA) and the precipitate discarded. The clarified lysate was immediately used for
affinity chromatography to purify protein. Lysis steps were checked via SDS-PAGE.
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3.2.5 Protein Purification
The clarified lysate was kept on ice during all purification steps and all buffers
were sterile filtered with 0.22 µM PES and vacuum degassed. For purification, the StrepTactin XT- 4Flow high capacity (IBA Lifesciences, Germany) pre-packed 5 mL cartridge
was connected to a BioLogic LP (Bio-Rad, USA) system with lysis buffer (described
above) as “buffer A” and elution buffer containing lysis buffer plus 50 mM biotin as
“buffer B.” All flow rates were 2.5 ml/min. The column was equilibrated with 2 column
volumes (CV) buffer A before loading the lysate onto the column. After the lysate was
loaded, the column was washed with buffer A until the A280 consistently read 0.0
(approximately 5 CV). The protein was eluted with buffer B for 3 CV followed by
immediate regeneration of the column with 15 CV of a 3M MgCl2 solution. The MgCl2
was removed by washing the column with 15 CV of buffer A. For this process, 1.0 mL
fractions were collected for each step and purification checked by SDS-PAGE. Purified
protein was buffer exchanged into 100 mM ammonium bicarbonate by concentrating the
protein eluate in a 7 MWCO spin concentrator (Fisher, USA). Once the volume reached
approximately 0.5 mL, 100 mM ammonium bicarbonate was added to the 20 mL fill line
and the sample centrifuged at 4000 x g at 4 °C. This process was repeated for a total of 4
centrifugations to ensure that no elution buffer remained in the sample. This sample was
then concentrated to make ~1.0 mL aliquots containing ~10.0 mg protein and lyophilized
on a LabConco lyophilizer overnight. Lyophilized samples were stored at -20 °C.
Concentrations were estimated using both BCA assay kit (Thermofisher, USA) and by
A280 readings using Beer’s Law.
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3.2.6 Circular Dichroism of Wild-Type and Mutant Constructs.
Purified lyophilized samples were reconstituted into 50 mM sodium phosphate
buffer, pH 7.5, containing 100 mM NaF, and 1 mM TCEP. CD spectra were collected
using a Jasco J-810 spectropolarimeter. Wild-type fortilin was measured at 0.1117
mg/mL, fortilin CGly56 was measured at 0.0980 mg/mL, and fortilin NSer46 was
measured at 0.1050 mg/mL. Samples were analyzed in a 0.1 cm cuvette at 20 °C. Three
spectra were collected for each sample at 1 nm intervals from 275 nm to 170 nm. Three
baseline spectra were collected using the same instrument parameters. The sample and
baseline spectra were averaged, and the baseline spectra were subtracted from the sample
spectra. The resulting spectra were converted from theta machine units (θ) to delta
epsilon units (Δε) using the following equation:
∆𝜀𝜀 = 𝜃𝜃 ×

0.1 × 𝑀𝑀𝑀𝑀𝑀𝑀
𝑃𝑃 × 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 × 3298

where θ = machine unit, mean residue weight (MRW) = protein weight
(Da)/number of residues – 1, path length (P) = cuvette path length (cm), protein
concentration (CONC) = protein concentration in mg/mL. The resulting spectra were
analyzed with the DichroWeb server, using the CDSSTR analysis program and reference
set 4.154–156
3.2.7 3D NMR Resonance Sample Preparation and Conditions
Lyophilized, 15N/13C-labeled mutant protein was prepared in ~10 mg aliquots.
CGly56 mutant protein was prepared in 500 µL of a 50 mM sodium phosphate pH 7.5,
200 mM NaCl, 1 mM TCEP with 0.1 mM TSP in D2O added as a reference standard.
CSer46 mutant protein was prepared in 500 µL of a 50 mM sodium phosphate pH 7.5, 50
mM NaCl, 1 mM TCEP with 0.1 mM TSP in D2O added as a reference standard.
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3.2.8 1H/15N-HQSC NMR Sample Preparation and Conditions.
For SMI titrations, approximately 2 mg 15N-labeled lyophilized protein was
resuspended in 500 µL of NMR buffer containing 50 mM sodium phosphate, pH 7.8, 50
mM NaCl, 0.1 mM TSP, 10% D2O and 1 mM d-DTT. 1-2 µL of a 10 mM SMI stock was
added for each titration point. For calcium titrations, 2 mg 15N-labeled lyophilized protein
was resuspended in 500 µL of buffer containing 20 mM Tris-Cl pH 7.4, 200 mM NaCl,
10% D2O and 1 mM d-DTT. 1-2 mL of a 1 M CaCl2 stock solution was added for each
titration point, up to a total of 20 µL calcium.
3.3 Results and Discussion
3.3.1 Expression and Purification of Mutant Constructs
Expression and purification yielded high quantities of recombinant fortilin mutant
protein (Table 3.1). These amounts are ideal for NMR analysis because high quantities
are required, as NMR is a relatively insensitive technique.148 Purification was checked by
SDS-PAGE and can be found in Appendix B, Figures B1-B5. Protein concentrations
were estimated via A280 measurement or by bicinchoninic acid (BCA) assay using a
standard calibration curve with bovine serum albumin (BSA). In brief, BCA assay is
performed by making a diluted standard curve of BSA and chelating with Cu2+ to form
Cu1+ in an alkaline environment followed by reaction with BCA for colorimetric
detection and measurement at λ = 562 nm. Replicate samples with protein are treated
with copper and then BCA in the same manner as BSA. Comparison is made to the
standard curve to approximate the concentration in mg/ml with a detection limit of 2.0
mg/ml.
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Table 3.1.
Yield in mg of fortilin construct after final purification steps.
*Lyophilized aliquots are in 2 mg amounts for 15N labeled, and 10 mg aliquots for
15
N/13C labeled protein.
Construct

Label type
15

CGly56
NGly56
NSer46

N
N
15
N
15

Yield
(mg)
8.15
15.66
6.34

# of lyophilized
aliquots*
4
7
3

3.3.2 Structural Analysis of Mutant Constructs
3.3.2.a Circular Dichroism of Secondary Structures of CGly56 and NSer46
Versus WT Fortilin
The structure of the fortilin mutant constructs appears to be conserved when the
affinity tag is placed within the flexible loop when analyzed by both circular dichroism
and NMR spectroscopy. Changes to the α-helical, β-strand, turn and unordered structures
determined by CD can be found in Table 3.2. According to the secondary structure
analysis, the NSer46 construct appears to be the closest in secondary structure to the
wild-type construct (Figure 3.3). These results indicate that the introduction of eight
consecutive amino acid mutations within the flexible loop region of fortilin does not
considerably change the secondary structure of fortilin. This is a promising result for
future analysis with SMIs to perform titrations wherein binding is predicted at the N and
C termini of fortilin.
Table 3.2
Calculated secondary structure percentages for WT fortilin and two
of the loop mutants.
Sample
WT
CGly56
NSer46

Total αhelical
9
9
9

Total βstrand
33
36
34

Turns

Unordered

NRMSD

23
22
24

35
33
33

0.040
0.016
0.033
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The overall α-helical structure remains exactly the same for each construct,
indicating that no changes to the α-helical content are made when introducing mutations
within the flexible loop. The overall β-strand content has changed, but only slightly, for
each construct, remaining relatively unchanged along with the total turns and unordered
structure of the protein. These findings are consistent with previous findings of the
rigidity of the majority of the structure of fortilin.79 While both constructs are similar in
secondary structure to the native protein, the NSer46 constructs is slightly closer overall.
The normalized root mean standard deviation (NRMSD) value is an indication of the
goodness of fit for the data to the reference set used, with NRMSD < 0.05 being
considered a good fit. For the data collected, all spectra have relatively low NRMSD
values ranging from 0.016 to 0.040 (Table 3.2).

Figure 3.3
Structural integrity of fortilin is conserved in mutant constructs. CD
spectra showing the secondary structure analysis of wild-type (black) versus CGly56
(pink) and NSer46 (blue).
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3.3.3 NSer46 (007)
3.3.3.a 1H/15N-HSQC Comparisons to Wild Type Fortilin
The NSer46 mutant construct was analyzed by NMR spectroscopy and the 1H15N
HSQC spectra compared to wild-type fortilin-strep protein. The spectrum of the
fingerprint region of mutant fortilin appears to be relatively conserved when compared to
the same chemical shift region as WT (Figure 3.4). The greatest changes to the spectra
appear at the dimensions indicated by boxes and arrows where peaks have either shifted
from the wild-type (in red) peak or appeared as new peaks in the spectrum. The amino
acid Q121, which contains two amino groups (one in the backbone and one in the side
chain) has shifted in the spectrum slightly, which may indicate a slight change in the
overall structure near that residue. There are two new peaks at ppm values of {10.5, 115}
and {6.01, 115}, which may be amino acids from the affinity tag, though sequential
backbone assignments are required to confirm this.
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Figure 3.4. A comparison of wild type fortilin and the NSer46 mutant construct
as shown by 1H/15N-HSQC NMR spectroscopy. The wild type fortilin spectrum
(red) is overlayed with the mutant construct spectrum (black) to observe differences
in peak signals. When overlayed most signals remained the same, with the few
differing signals likely accounting for the strep tag mutation.
3.3.3.b NMR Titration with Calcium
To confirm whether in vitro biological activity was conserved after the
introduction of mutations within the flexible loop, we performed calcium titrations with
NSer46. As increasing amounts of CaCl2 are added, peaks are observed to shift (Figure
3.5). The peak for amino acid Y132 was chosen as a representative peak for calcium
binding, because it has been used previously to determine Kd values, and it appears to
shift the most dramatically over the course of Ca2+ titration.79,150 These results are
consistent with previously published data.79
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Figure 3.5. An overlay of 1H/15N-HSQC spectra during a Ca2+ titration
experiment with NSer46. The residue peaks shift hot (red) to cold (blue) colors with
the addition of CaCl2. Y132 (indicated with a black arrow) showed a prominent
downfield shift during the titration with Ca2+, consistent with literature reports for
WT fortilin (shift is indicated by an arrow).
The calcium titration data were analyzed using the Langmuir binding
isotherm:

𝐾𝐾𝑑𝑑+𝐿𝐿+𝑅𝑅−�(𝐾𝐾𝐾𝐾+𝐿𝐿+𝑅𝑅)2 −4𝑅𝑅𝑅𝑅
2𝑅𝑅

∗ 𝐵𝐵𝑚𝑚𝑚𝑚𝑚𝑚 where L = ligand and R = receptor

concentrations. The peak for Y132 was followed and the changes in 1H and 15N chemical
shifts recorded as calcium concentration increased. Using this binding fit for the data, a
dissociation constant of 27.8 ± 4.63 mM was calculated for NSer46 to calcium (Figure
3.6).
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Figure 3.6.

Calcium binds NSer46 mutant fortilin with an estimated dissociation
constant of 27.8 ± 4.63 mM.

3.3.4 CGly56 (004)
3.3.4.a 1H/15N-HSQC of CGly56
The fortilin mutant construct fingerprint 1H/15N-HSQC spectrum appears to be of
a similar nature to the wild type and NSer46 constructs, indicating a conserved structure
(Figure 3.7). Differences is spectral quality in Figure 3.7 are attributed to the spectra
being recorded on different resolution spectrometers. The CGly56 construct HSQC was
recorded on an 800 MHz spectrometer, which being a higher field strength, provides
higher resolution spectra. There are some changes in appearance between the fingerprint
spectra of WT versus NSer46 and CGly56 indicated in Figure 3.7. Sequential backbone
assignments and 3D structural data must be complete to obtain full structural information
on these constructs.
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Figure 3.7. A comparison of CGly56 mutant fortilin (blue) 1H/15N-HSQC NMR
spectrum overlaid on the spectrum of NSer46 mutant construct (green). The
spectral overlay shows high structure homology, with differing signals most likely
attributable to the strep tag location. Major differences in peak signal are boxed.
3.4 Conclusions & Future Directions
Loop mutant constructs were generated with the purpose of removing the
possibility of residual amino acids at the N and C termini of fortilin, such that activity
studies may be performed were binding at the N or C termini may be performed. The
mutant constructs appear to have good conservation of secondary and tertiary protein
structure as compared to WT fortilin when analyzed by both CD and NMR spectroscopy.
The NSer46 mutant has conserved Ca2+ binding affinity and is relatively similar to the Kd
estimated with native fortilin of between 22 and 25 mM that was also determined by
NMR spectroscopy following Y132.79 The next step for this project is to complete
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calcium titrations for all mutant constructs as well as to solve the solution structures by
NMR spectroscopy to confirm the CD and HSQC results. While the data presented here
provide evidence to the structural integrity of fortilin mutants, solving the solution
structures will aid in confirming that the overall structure of fortilin has not been changed
significantly by the introduction of loop mutants. This is done by first collecting 3D
spectra to coordinate the fingerprint 1H/15N-HSQC to the 3D spectra to make sequential
peptide backbone assignments followed by molecular minimizations with nuclear
Overhauser effect spectroscopy (NOESY) data to determine through-space couplings
between atoms. This will be done to confirm the structural integrity of the mutant
proteins.

78

CHAPTER FOUR: PRELIMINARY STRUCTURE ACTIVITY STUDIES OF
FORTILIN
Maranda S. Cantrell (unpublished)
4.1 Introduction
The determination of binding sites on protein targets is crucial to the rational drug
design process. By determining different positions on a protein where a drug target may
bind, changes can be made to the drug target to allow for more binding specificity and
drug efficacy. There are three popular methods used today to structurally characterize
protein binding sites and these are cryo-electron microscopy (cryo-EM), X-ray
crystallography and NMR. Cryo-EM is an emerging technique that has gained popularity
in recent years for its simple sample preparation methods and ease of use. However, it is
a relatively expensive technique and cryo-EM equipment is not yet widely available. Xray crystallography requires the formation of crystals, which can be nontrivial to make
and can take many months or even years to form, let alone crystallizing a protein-target
complex, which involves yet more method development. NMR, in comparison, is a more
rapid technique, although the amount of protein required for NMR studies are quite high,
in the mg range, and solubility can be a limiting factor. Another drawback of NMR is that
proteins ideally must range in size between 1 and 50 kDa for optimal analysis. As the size
of the protein analyzed gets larger, too many signals complicate the spectra and
subsequent analysis. Fortilin is a 19 kDa protein that can now be expressed in mg
quantities, making it a suitable candidate for analysis by NMR spectroscopy.
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Molecular dynamics (MD) is a powerful tool used to provide a basis level of
understanding the lowest energy conformation of many molecules and proteins. MD is
often used for predicting where and how a ligand may interact with a target in the
absence of experimental data. Additionally, many MD programs, such as GROMACS,
are free to use and widely available to researchers.157 MD in conjunction with a docking
program like Autodock Vina can be used to perform high throughput screening (HTS)
methods, like the computational prediction for large quantities of molecules contained in
electronic databases. Computational HTS is an ideal tool to use prior to experimental
screening of SMIs to proteins, because it is incredibly cost effective, rapid and provides
valuable structure-function insights.
Before using an expensive experimental technique such as NMR, X-ray and cryoEM, assays should be performed to determine the best conditions for stability of the
protein, as well as small molecule binding assays to determine which drugs analyzed will
bind the protein target. Drug candidates that show promise in early assays may be taken
on to NMR analysis to determine their binding site on the protein and can then move
forward in the drug design process. Fortilin was analyzed by computational screens as
well as differential scanning fluorimetry (DSF) to determine the optimal buffer
conditions to keep the protein stable in solution, at the concentration needed for NMR
experiments, as well as perform a small molecule screen to see identify which candidates
may be used in NMR determination of binding site location.
DSF, also known as “thermal shift assay,” is a technique that was first developed
in 1991 by Semisotnov et al., and improved for its use with quantitative polymerase chain
reaction (qPCR) equipment by Pantoliano et al., in 1997.158,159 The general workflow for
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this technique is that the protein is denatured over a temperature gradient and the melting
temperature of the protein is recorded as a fluorescent reporter signal. Fluorescent
reporters may be intrinsic to the protein, such as a green fluorescent protein (GFP) tag or
via the use of a tryptophan residue(s), or they may be extrinsic, such as SYBR orange or
other commercially available dyes. As your protein denatures with the increase in
temperature, the dye binds to hydrophobic residues in the protein and the fluorescent
signal increases with rising temperature. For TCTP, the use of an extrinsic dye is
necessary, because TCTP does not contain tryptophan residues. Stability assays of the
protein are first performed with a buffer screen to determine the average melting
temperature of the protein as well as determine the optimal buffer conditions. Next, a
SMI screen may be performed. Addition of small molecule drugs to the sample can either
increase (stabilize) or decrease (destabilize) protein stability and provide a yes/no answer
as to whether a SMI should be considered for NMR titration experiment. The results
presented here are from DSF screening for buffer stability as well as SMI binding to
determine the candidates that could go on for study by NMR spectroscopy. We used SMI
candidates to perform NMR titrations with different TCTP recombinant protein
constructs to determine potential binding site residues on TCTP.
4.2 Materials and Methods
4.2.1 Computational Docking using Autodock Vina
The solution NMR structure of fortilin has been determined.79 The PDB file for
this structure, 2HR9 was used for all experiments. Drug candidate structures were
provided by our collaborator Dr. Brian Blagg at Notre Dame University and docking
performed on structures with Kd values below 10 nM (determined experimentally using
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SPR by Dr. Blagg’s group and can be found in Table 4.1. GROMACS software was used
to perform molecular dynamics on fortilin to find the lowest energy structure using the
AMBER03 force field and TIP3P water model.157,160 The AMBER03 force field was
chosen because it is most applicable to MD simulations with proteins, as each amino acid
within the protein is allowed its main charge, if need be and is designed for solution
phase simulations.161 The TIP3P water model was chosen because its rigid water
molecule model is ideal for HTS and it has a relatively low computational cost.162 The
protein was solvated in a cubic box and ions added to make the protein neutral in charge.
Energy minimizations at constant pressure (NVT) and constant temperature (NPT) were
performed before minimizing the final structure.
Once minimized, Autodock Vina software v.1.1.2 was used to perform molecular
docking of the drug candidates in Table 4.1 to predict their binding sites.22 Simulations
were run such that fortilin was made to be a rigid structure, which is not ideal for a realworld situation, but is necessary for higher throughput screening of drug candidates to
obtain information in a time-sensitive manner.
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Table 4.1.
Structures used for computational docking experiments to estimate
Kd values for binding to WT fortilin. The Kd values displayed in this table were
experimentally determined using SPR.
Urea Compound

Compound
Name
AZU_3
AZU_6
AZU_8
AZU_9
AZU_13
AZU_20
AZU_22
AZU_23

X
m-Cl, p-Cl
m-Cl, p-Cl
m-Cl
o-Cl
m-CH3
m-Cl, p-Cl
m-Cl, p-Cl
m-Cl, p-Cl

Y

R1

p-OH
CH3
o-OH
CH3
o-OH
CH3
o-OH
CH3
o-OH
CH3
p-F
CH3
p-NO2
CH3
p-CH3
CH3
Thiourea Compound

AZTU_5
AZTU_6
AZTU_7
AZTU_8

m-Cl, p-Cl
o-OH
H
m-Cl, p-Cl
o-OH
CH3
p-Cl
o-OH
CH3
m-Cl
o-OH
CH3
Thiourea hydroazide compound

AZTH_1
AZTH_7

H
3-OMe, 4OMe
3-OMe, 4OMe, 5OMe

AZTH_12

R2

Kd (nM)

Ph-CH2
CH3CH2
Ph-CH2
Ph-CH2
Ph-CH2
Ph-CH2
Ph-CH2
Ph-CH2

0.46
1.6
0.81
1.74
1.26
1.55
0.01
4.90

Ph-CH2
CH3CH2
Ph-CH2
Ph-CH2

9.54
0.03
1.29
1.89

---

o-Cl
o-Cl

---

2.66
4.53

--

o-Cl, m-Cl

--

2.46

83
4.2.2 Differential Scanning Fluorimetry of Fortilin-Strep
4.2.2.a Buffer Screen to Determine Optimal Conditions for Fortilin Protein
Recombinant fortilin-strep (preparation described in section 3.2) was resuspend in
a dilution buffer containing 10 mM sodium phosphate (NaPi), pH 7.5 and 10 mM NaCl
to a final concentration of 100 µM. To this solution, either 10 or 20 µL (done to
determine an optimal dye concentration) of a 5000 X stock of SYPRO Orange
fluorescent dye in DMSO (Thermofisher, USA) was added. Stocks (5X) of the buffers
described in Table 4.2 were prepared. To each well in a 0.2 mL 96-well plate, 40 µL of
protein solution was added with 10 µL of the corresponding 5X buffer solution. The
samples were run on a Quant Studio 3 Real Time PCR System (Thermofisher, USA). The
temperature gradient was as follows: 25 ºC hold for 1 min, 1 ºC/s to 95 ºC, hold 95 ºC for
2 min, return to 25 ºC.
Table 4.2
Buffer screen conditions for fortilin-strep. A total of 30 unique buffer
conditions were used for this analysis.
Buffer
50 mM NaPi
50 mM HEPES
50 mM Tris
1X PBS

[NaCl], mM
50 mM
150 mM
250 mM
50 mM
150 mM
250 mM
50 mM
150 mM
250 mM
none

pH
6.5, 7.0, 7.5
6.5, 7.0, 7.5
6.5, 7.0, 7.5
7.0, 7.5, 8.0
7.0, 7.5, 8.0
7.0, 7.5, 8.0
7.0, 7.5, 8.0, 8.5
7.0, 7.5, 8.0, 8.5
7.0, 7.5, 8.0, 8.5

4.2.2.b SMI Screen for Potential Hits
Fortilin-strep at 100 µM in a 1X PBS solution was prepared containing 20X
SYPRO orange dye. To each well, 48 µL of fortilin solution was added along with 2 µL
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of a SMI stock solution of 10 µM. The SMI molecules used, in duplicates, for this study
were artemisinin, dihydroartemisinin (DHA), ampicillin, kanamycin, biotin, 10B4, 10B5,
10B6, 10B7, 26A3, 26A4, 10.3, 10.4 and 10.5. Structures with shortened names are SMIs
derived from the OSM project with Dr. Jorcyk’s lab and are protected intellectual
property. These samples were run with the same temperature gradient as described in
4.2.2.a.
4.2.3 NMR Titration Analysis with Small Molecules
Lyophilized protein (2 mg) of either wild-type, NSer46 or CGly56 was
reconstituted in 500 µL of NMR buffer (50 mM NaPi, pH 7.5, 50 mM NaCl, 10% D2O,
0.1 mM TSP, 16 µM reducing agent [DTT or TCEP]). 1H/15N-HSQC spectra were
collected on a Bruker 600 MHz NMR spectrometer fitted with a cryoprobe. SMIs tested
against these constructs included 26A3 (10 mM stock in DMSO), 11CO9 (50 mg/ml
stock in DMSO) or artemisinin (10 mg/ml stock in DMSO). For each titration, 1-2 µL of
SMI was added into the NMR sample and spectra recorded at 37 ºC. SMI was added and
titration samples run until either the SMI stock crashed in solution or sample was
depleted. Filenames and parameters may be found in Appendix D.
4.3 Results and Discussion
4.3.1 Computational Docking Results
The root-mean-square deviation (RMSD) structure of the last 50 ps of the
minimization for the backbone of the protein relative to the equilibrated structure can be
seen in Figure 4.1. The structure determined from the minimization versus the NMR
solution structure have little difference in value. The MD results are expected to be
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similar to the experimental RMSD for the structure, as NMR structures are typically
rendered as the lowest energy structure.

Backbone RMSD MD vs. NMR Structure of Fortilin
0.5

RMSD (nm)

0.4
0.3
0.2
0.1
0.00
0.04
0.08
0.12
0.16
0.20
0.24
0.28
0.32
0.36
0.40
0.44
0.48
0.52
0.56
0.60
0.64
0.68
0.72
0.76
0.80
0.84
0.88
0.92
0.96
1.00

0

Time (ns)
MD Structure

Figure 4.1.

NMR Structure

RMSD structure derived from the MD simulation vs. the solution
derived NMR structure.

For the purpose of simplicity, the docked structure that will be discussed in some
detail is AZU_22, which has the lowest experimental Kd value (001 nm). Docking
experiments performed determined the lowest energy conformation of AZU_22 to fortilin
seen in Figure 4.2. A binding affinity of -5.6 kcal/mol was predicted for the best fit
conformation. In comparison with the experimentally determined binding affinity
(assuming T=298 K) of -14.9 kcal/mol, this leaves an error of 62.4 %.
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Figure 4.2
Left) Molecule AZU_22 docked onto fortilin with flexible loop cut off
for ease of visualization. Right) Residues labeled within 1 Å of AZU_22.
The binding affinities and theoretical error are listed in Table 4.3. The percent
error is fairly high across the SMIs with an average error of 55.6 ± 4.0 %. One possible
explanation for this result is that making the structure completely inflexible and using a
rigid water molecule model was not ideal for this experiment. What could be done is
allowing for some flexible side chains within the box of allowed binding for small
molecule inhibitors since this was not a true HTS computational experiment and the
computational cost decreases with the lowered amount of SMIs for screening.
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Table 4.3
Experimental and predicted binding affinity values from SPR versus
computational docking experiments with Autodock Vina.
Compound Name
AZU_3
AZU_6
AZU_8
AZU_9
AZU_13
AZU_20
AZU_22
AZU_23
AZTU_5
AZTU_6
AZTU_7
AZTU_8
AZTH_1
AZTH_7
AZTH_12

Experimental Binding
Affinity (kcal/mol)
-12.7
-11.9
-12.4
-11.9
-12.1
-12.0
-14.9
-11.3
-10.9
-14.3
-12.1
-11.9
-11.7
-11.3
-11.7

Predicted Binding Percent Error (%)
Affinity (kcal/mol)
-5.8
54.3
-5.2
56.3
-5.6
54.8
-5.3
55.5
-5.6
53.7
-5.5
54.2
-5.6
62.4
-5.7
49.6
-5.5
49.5
-5.4
62.2
-5.1
57.9
-4.6
61.3
-5.1
56.4
-5.3
53.1
-5.5
53.0

The docking experiments performed may not be entirely representative of the
binding interactions that will be determined by NMR spectroscopy. This is because the
structure utilized by Autodock Vina was entirely rigid, with no flexibility allowed. Future
docking experiments should be performed to allow for flexible side chains such that more
realistic binding information can be predicted. However, without NMR data to determine
fortilin binding sites for small molecule inhibitors, no reliable docking information can be
obtained. Knowledge of where a small molecule binds experimentally is required to make
accurate predictions for future docking studies. The NMR titrations were performed to
determine the binding sites with the first round of drug candidates. The ultimate goal of
this research is to develop more drugs for atherosclerosis, so that we will be one step
closer once binding information to small molecule inhibitors is obtained.
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4.3.2 DSF Buffer Screen Results
Fortilin was determined to be stable in a wide variety of buffers across a wide
range of pH values. The most stable pH range was 7.0 to 8.0. There appeared to be no
major differences in buffer selection as long as the pH was within the optimal range
(Figure 4.3). The average melting temperature (Tm) was calculated to be 65.08 ºC in 1X
PBS for this experiment. To my knowledge, this is the only recorded Tm for recombinant
fortilin protein available. Additionally, this screen was performed using two different
concentrations of SYPRO Orange dye (10X or 20X). While the majority of the conditions
appear to show little difference in Tm based on dye concentration, a few of the conditions
had some clear differences in signal. These include 50 mM HEPES, 250 mM NaCl, pH
8.0; 50 mM Tris, 150 mM NaCl, pH 8.0; and one of the 1X PBS samples. Further studies
need to be performed to optimize SYPRO Orange dye concentrations in the sample along
with careful attention to pipetting error, as these may have contributed to the differing
results.

Figure 4.3
Fortilin is stable in a pH range of 6.5 to 8.0 and in a wide variety of
buffers at two different SYPRO Orange concentrations. Fortilin has a melting
temperature of 65.08 ºC.
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4.3.3 DSF SMI Screen Results
For SMI screens using DSF, an indication that a protein binds a given target is
indicated by a change in Tm of the protein. This can be either a stabilizing compound,
wherein the Tm for the protein increases, or this can be a destabilizing compound,
wherein the Tm for the protein decreases. As a general rule, a change of Tm by
approximately 2 ºC can be considered a “hit” for binding. Unfortunately, no real
significant hit was obtained for fortilin based on this requirement. The SMIs tested
against fortilin and the change in Tm is shown for molecules that changed the Tm by
anything over 1 ºC (Figure 4.4). Calcium, well established as a binder to fortilin,
changed the Tm significantly to 68.418 ºC. A few candidates were chosen from this data
and used to evaluate binding via NMR spectroscopy, namely 11C09 and 26A3.

Figure 4.4

SMI screen of fortilin-strep using DSF.

At first glance, hemin as well as hemin + artemisinin appeared to alter the Tm of
fortilin greatly. However, by looking at the actual melting curve itself, we see that the
data is inconclusive for both samples, as represented in Figure 4.5. The left side of
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Figure 4.5 shows an ideal derivatized melting curve plot for DSF SMI screening, while
the plot for the hemin addition to the sample is shown on the right.

Figure 4.5

DSF melting curve derivative plot of hemin with fortilin strep (right)
with a representative melting curve with no SMI bound (left).

While the addition of hemin and hemin + artemisinin appeared at first to have
altered the melting temperature of fortilin-strep, a further look at the graphical
representation of the melting curve showed no observed binding and an incomplete
spectrum (Figure 4.5). This is likely due to hemin’s colorful hue, as it is a black powder.
Indeed, hemin absorbs in an overlapping wavelength range as SYPRO Orange (400-430
nm and 450-550 nm, respectively.163 This being a fluorometric assay, the color of hemin
may interfere with the signal received by the PCR machine and as a result DSF may not
be the best method to determine a “hit” for binding of hemin to fortilin.
4.3.4 NMR Titration Results
4.3.4.a Fortilin-Strep with 11CO9
The SMI 11CO9 is a molecule that was sent by our collaborator and has shown
promise as a candidate for a novel atherosclerosis drug in in vivo animal studies. The
structure is currently undergoing patenting and therefore cannot be shared here. This
titration led to no observed binding during NMR experiments (Figure 4.6). For
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simplicity, only the first and last spectrum are shown. This was after 20 µL of titrant had
been added to the solution and no binding observed.

Figure 4.6. Titration of fortilin-strep with SMI 11CO9. Increasing amounts of
11CO9 appear from the first spectrum (1 µL stock, purple) to the last spectrum (20
µL stock, green). Binding was not observed using NMR spectroscopy.
4.3.4.b CGly56
Artemisinin is an anti-malarial drug and has been shown experimentally to bind
the P. falciparum fortilin protein, whose protein sequence can be found in Figure 1.6.114
Because the structural homology of different species of fortilin is so highly conserved, we
hypothesized that artemisinin would bind in a similar location on the protein and with
similar affinity. However, titration analysis with CGly56 indicated no binding with
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artemisinin (Figure 4.7). This analysis was repeated with similar results on NSer46 (data
not shown).

Figure 4.7

Binding is not observed with mutant construct CGly56 and antimalarial drug artemisinin.

4.3.4.c NSer46
The SMI 26A3 is a synthesized molecule made by researchers in Dr. Don Warner’s lab at
Boise State University. This molecule did not appear to have binding with NSer46,
however the sample was depleted before the ideal stopping point of titration, so further
analysis with this SMI is required to determine whether 26A3 really does not bind fortilin
(Figure 4.8). We have preliminary binding curve data extrapolated from the shifts in the
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HSQC to obtain preliminary Kd values for each shifting residue.

A

B

V31
Q121
D165
T157
E109

Figure 4.8. Mutant fortilin NSer46 potentially binds SMI 26A3. A) observed peak
shifts are questionable with the current data. Arrows indicate the direction of the
potential peak shift and corresponding amino acids are labeled. B) Binding curves
extrapolated from the data for a given peak shift.
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4.4 Conclusions & Future Directions for This Dissertation
The results presented in this body of work portend to the preliminary research
conducted in order to perform structural activity relationships with recombinant fortilin
protein. In Chapter 2, a recombinant fortilin construct was developed such that the first
ever cleaved construct with no affinity tag could be produced. In Chapter 3, loop mutant
constructs were generated such that potential binding for ligands at the N- and C-termini
could be explored. In Chapter 4, the preliminary SMI binding studies were performed to
rule out SMIs that did not bind fortilin or the mutant constructs. There is much to be
explored for fortilin using NMR spectroscopy. Previous mass spectrometry data collected
by our lab indicate that there may be some PTMs on fortilin, indicated by the presence of
an 11 kDa difference in mass, that are not being accounted for in the recombinant E. coli
construct (Figure 4.9). When expressed in the human embryonic kidney (HEK) 293 cell
line, fortilin presents with a molecular weight of approximately 32 kDa. When expressed
in E. coli, fortilin presents with a molecular weight of 21 kDa. These differences may be
due to the presence of PTMs, though there is very little research done to support this.
Only three PTMs, acetylation, phosphorylation and ubiquination, have been confirmed
for fortilin.164–167
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Figure 4.9
Recombinant human fortilin expressed in HEK293 cells has a
significantly greater mass than fortilin expressed in E. coli. Mass spectrometry data
of A) HEK293-expressed fortilin (mw 32 kDa) and B) E. coli-expressed 6His-fortilin
(mw 21 kDa).
Future plans are to change to a yeast expression system in Pichia pastoris such
that potential glycosylation PTMs may be analyzed by NMR spectroscopy as well as
determine whether SMIs can bind. Isotopically labeling protein becomes more difficult
with a more complex cell system, but yeast expression for NMR is quite common.148
Additionally, the E. coli versus P. pastoris versus human cell line (HEK293, for
example) recombinantly expressed fortilin should be analyzed by mass spectrometry to
determine what PTMs may be present. In the past, most preliminary studies have been
performed with a recombinant GST-tagged fortilin that has not been cleaved. This
construct was used to determine that DHA bound fortilin, and artemisinin binding studies
have been performed with non-human fortilin constructs. These are indications that the
recombinant fortilin expressed in E. coli possesses significant differences to human
fortilin. A future student would be encouraged to explore the realm of PTM via the use of
isotopically labeled yeast-expressed fortilin as well as using mass spectrometry to
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determine the identification of potential PTMs present. There is much to do in the realm
of structural characterization and SMI binding determination of fortilin.
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APPENDIX A
Supplementary materials for Chapter Two – purification gels and mass
spectrometry data
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SDS-PAGE gels to check purification status

Figure A1.

(GGS)0 purification. GST-fortilin can be seen at approximately 47
kDa.

Figure A2.

(GGS)1 purification. Pure GST-GGS-fortilin can be seen at 47 kDa.
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Figure A3.

Figure A4.

(GGS)2 and (GGS)3 purification. Arrows point to GST-(GGS)Nfortilin.

6His-MBP-10N-3C-TEV-Fortilin purification. Arrow points to 6HisMBP-10N-3C-TEV-fortilin.
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Figure A5. 6His-TEV-fortilin and GST-3C-TEV-fortilin purification. Arrows
indicate purified 6His-TEV-fortilin (left) and GST-3C-TEV-fortilin (right).

Figure A6.

MBP-TEV-fortilin purification. Arrow indicates MBP-TEV-fortilin.
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Figure A7. 15N-GGS-fortilin cleavage and purification. Arrow indicates pure
GGS-fortilin after cleavage and subsequent purification on glutathione agarose. For
this sample, not enough 3C protease was initially added (day 1 lane). On day 5,
protease was added to a combined volume of 50 mL protease in the sample and ideal
cleavage was observed on day 7.
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Mass Spectrometry Analysis for Chapter Two.
Table A1.
Sample names and sequences for mass spectrometry analysis. These
data correspond to the following MS files in this section.
Sequence
name

sample
name

sample
from
what
construct
MBPTEVOSM

MC1

MBP +ctrl

MC2

OSM +ctrl

MBPTEVOSM

MC3

MBPTEV
Fortilin
TEV+ Day
1

MBPTEVFortilin

MC3

MBPTEV
Fortilin
TEV- Day 1

MBPTEVFortilin

expected sequence

MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH
PDKLEEKFPQ VAATGDGPDI IFWAHD
RFGGYAQSGLLAEI TPDKAFQDKL YPFTWDAVRY
NGKLIAYPIA VEALSLIYNK DLLPNPPKTW EEI
PALDKEL KAKGKSALMF NLQEPYFTWP LIAADGGYAF
KYENGKYDIK DVGVDNAGAKAGLTFLV
DLI KNKHMNADTD YSIAEAAFNK GETAMTINGP
WAWSNIDTSK VNYGVTVLPT FKGQPSKPFVGV
LSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL
GAVALKSYEE ELAKDPRIAATMENAQKG
EI MPNIPQMSAF WYAVRTAVIN AASGRQTVDE ALKDAQTNSS
SNNNNNNNNN NLGIEGR ENLYFQ
MGVLLTQRTLLSLVLALLFPSMASMAAIGSCSKEYRVLLGQLQK
QTDLMQDTSRLLDPYI
RIQGLDVPKLREHCRERPGAFPSEETLRGLGRRGFLQTLNATLGC
VLHRLADLEQRLPKA
QDLERSGLNIEDLEKLQMARPNILGLRNNIYCMAQLLDNSDTAE
PTKAGRGASQPPTPTP
ASDAFQRKLEGCRFLHGYHRFMHSVGRVFSKWGESPNRSRRHSP
HQALRKGVRRTRPSRK
GKRLMTRGQLPR
MKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDK
LEEKFPQVAATGDGPDIIFWAHDRF
GGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVE
ALSLIYNKDLLPNPPKTWEEIPALD
KELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIK
DVGVDNAGAKAGLTFLVDLIKNKH
MNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTV
LPTFKGQPSKPFVGVLSAGINAASP
NKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKD
PRIAATMENAQKGEIMPNIPQMSAF
WYAVRTAVINAASGRQTVDEALKDAQTNFQGPMENLYFQGIIY
RDLISHDEMFSDIYKIREIADGLCLE
VEGKMVSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVM
NHHLQETSFTKEAYKKYIKDYMKS
IKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPD
GMVALLDYREDGVTPYMIFFKDG
LEMEKCLE
MKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDK
LEEKFPQVAATGDGPDIIFWAHDR
FGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAV
EALSLIYNKDLLPNPPKTWEEIPAL
DKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDI
KDVGVDNAGAKAGLTFLVDLIKN
KHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYG
VTVLPTFKGQPSKPFVGVLSAGINA
ASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELA
KDPRIAATMENAQKGEIMPNIPQ
MSAFWYAVRTAVINAASGRQTVDEALKDAQTNFQGPMENLYF
QGIIYRDLISHDEMFSDIYKIREIA
DGLCLEVEGKMVSRTEGNIDDSLIGGNASAEGPEGEGTESTVITG
VDIVMNHHLQETSFTKEAYKKY
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MC5

TEV
Fortilin 3C+
Day 1

MC5

TEV
Fortilin
from GST
Day 1

MC7

GST3CTE
V Fortilin ctrl Day 1

GST-3CTEVFortilin

MC7

GST3CTE
V Fortilin
3C+ Day 1

GST-3CTEVFortilin

MC7

GST3CTE
V Fortilin
TEV+ Day
1

GST-3CTEVFortilin

MC10

6HisMBP
Fortilin -ctrl
Day 1

6HisMBP10N-3CTEVFortilin

6HisMBP10N-3CTEVFortilin
GST-3CTEVFortilin

IKDYMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFI
GENMNPDGMVALLDYREDGVTP
YMIFFKDGLEMEKCLE
MENLYFQGIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSR
TEGNIDDSLIGGNASAEGPEGEGT
ESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQ
RPERVKPFMTGAAEQIKHILANFK
NYQFFIGENMNPDGMVALLDYREDGVTPYMIFFKDGLEMEKC
MENLYFQGIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSR
TEGNIDDSLIGGNASAEGPEGEGT
ESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQ
RPERVKPFMTGAAEQIKHILANFK
NYQFFIGENMNPDGMVALLDYREDGVTPYMIFFKDGLEMEKC
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRN
KKFELGLEFPNLPYYIDGDVKLTQS
MAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSK
DFETLKVDFLSKLPEMLKMFEDRL
CHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCF
KKRIEAIPQIDKYLKSSKYIAWPLQ
GWQATFGGGDHPPKSDLEVLFQGPMENLYFQGIIYRDLISHDEM
FSDIYKIREIADGLCLEVEGKMVS
RTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETS
FTKEAYKKYIKDYMKSIKGKLEE
QRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALL
DYREDGVTPYMIFFKDGLEMEKC
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRN
KKFELGLEFPNLPYYIDGDVKLTQS
MAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSK
DFETLKVDFLSKLPEMLKMFEDR
LCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVC
FKKRIEAIPQIDKYLKSSKYIAWP
LQGWQATFGGGDHPPKSDLEVLFQGPMENLYFQGIIYRDLISHD
EMFSDIYKIREIADGLCLEVEGKM
VSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQE
TSFTKEAYKKYIKDYMKSIKGKL
EEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVA
LLDYREDGVTPYMIFFKDGLEM
EKC
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRN
KKFELGLEFPNLPYYIDGDVKLT
QSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAY
SKDFETLKVDFLSKLPEMLKMFE
DRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKL
VCFKKRIEAIPQIDKYLKSSKYIA
WPLQGWQATFGGGDHPPKSDLEVLFQGPMENLYFQGIIYRDLIS
HDEMFSDIYKIREIADGLCLEVEG
KMVSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHH
LQETSFTKEAYKKYIKDYMKSIK
GKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDG
MVALLDYREDGVTPYMIFFKDG
LEMEKC
MHHHHHHKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVT
VEHPDKLEEKFPQVAATGDGPD
IIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGK
LIAYPIAVEALSLIYNKDLLPNP
PKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAF
KYENGKYDIKDVGVDNAGAK
AGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAW
SNIDTSKVNYGVTVLPTFKGQPS
KPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPL
GAVALKSYEEELAKDPRIAATM
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MC10

6HisMBP
Fortilin 3C+
Day 1

6HisMBP10N-3CTEVFortilin

MC10

6HisMBP
Fortilin
TEV+ Day
1

6HisMBP10N-3CTEVFortilin

MC10

6HisMBP
3C+ Day 1

6HisMBP10N-3CTEVFortilin

MC14

MBP TEV+
Day 1

6HisMBP10N-3C-

ENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDA
QTNLEVLFNSSSNNNNNNNNNN
LGIEGRISHMLEVLFQGPMENLYFQGIIYRDLISHDEMFSDIYKIR
EIADGLCLEVEGKMVSRTEGNID
DSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYK
KYIKDYMKSIKGKLEEQRPERV
KPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYRED
GVTPYMIFFKDGLEMEKCLE
MHHHHHHKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVT
VEHPDKLEEKFPQVAATGDGP
DIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNG
KLIAYPIAVEALSLIYNKDLLP
NPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGY
AFKYENGKYDIKDVGVDNAGA
KAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWA
WSNIDTSKVNYGVTVLPTFKG
QPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKD
KPLGAVALKSYEEELAKDPR
IAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDE
ALKDAQTNLEVLFNSSSNNN
NNNNNNNLGIEGRISHMLEVLFQGPMENLYFQGIIYRDLISHDEM
FSDIYKIREIADGLCLEVEGK
MVSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHL
QETSFTKEAYKKYIKDYMKS
IKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPD
GMVALLDYREDGVTPYMIFF
KDGLEMEKCLE
MHHHHHHKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVT
VEHPDKLEEKFPQVAATGDGPD
IIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGK
LIAYPIAVEALSLIYNKDLLPNPP
KTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAF
KYENGKYDIKDVGVDNAGAKAG
LTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSN
IDTSKVNYGVTVLPTFKGQPSKP
FVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGA
VALKSYEEELAKDPRIAATMEN
AQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQT
NLEVLFNSSSNNNNNNNNNNL
GIEGRISHMLEVLFQGPMENLYFQGIIYRDLISHDEMFSDIYKIREI
ADGLCLEVEGKMVSRTEGNID
DSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYK
KYIKDYMKSIKGKLEEQRPER
VKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYRE
DGVTPYMIFFKDGLEMEKCLE
MHHHHHHKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVT
VEHPDKLEEKFPQVAATGDG
PDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYN
GKLIAYPIAVEALSLIYNKDLLP
NPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGY
AFKYENGKYDIKDVGVDNAG
AKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPW
AWSNIDTSKVNYGVTVLPTFK
GQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNK
DKPLGAVALKSYEEELAKDPR
IAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDE
ALKDAQTNLEVLFNSSSNNNN
NNNNNNLGIEGRISH
MHHHHHHKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVT
VEHPDKLEEKFPQVAATGDG
PDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYN
GKLIAYPIAVEALSLIYNKDLL

127
TEVFortilin

MC14

MBP TEVDay 1

6HisMBP10N-3CTEVFortilin

MC16

6HisTEV
Fortilin
TEV- Day 1

6HisTEVFortilin

MC16

6HisTEV
Fortilin
TEV+ Day
1

6HisTEVFortilin

MC18

15N(GGS)1
-fortilin
(this is 15N
labeled)

GST-3C(GGS)1Fortilin

PNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGG
YAFKYENGKYDIKDVGVDN
AGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTING
PWAWSNIDTSKVNYGVTVLP
TFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEA
VNKDKPLGAVALKSYEEELAK
DPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQT
VDEALKDAQT
MHHHHHHKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVT
VEHPDKLEEKFPQVAATGDGP
DIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNG
KLIAYPIAVEALSLIYNKDLLP
NPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGY
AFKYENGKYDIKDVGVDNAG
AKAGL
TFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNI
DTSKVNYGVTVLPTFKGQPS
KPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPL
GAVALKSYEEELAKDPRIAAT
MENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKD
AQT
MHHHHHHMENLYFQGIIYRDLISHDEMFSDIYKIREIADGLCLEV
EGKMVSRTEGNIDDSLIGGNA
SAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYM
KSIKGKLEEQRPERVKPFMTG
AAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPYMI
FFKDGLEMEKCLE
MHHHHHHMENLYFQGIIYRDLISHDEMFSDIYKIREIADGLCLEV
EGKMVSRTEGNIDDSLIGGN
ASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDY
MKSIKGKLEEQRPERVKPFM
TGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTP
YMIFFKDGLEMEKCLE
GGSMIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNI
DDSLIGGNASAEGPEGEGT
ESTVITGVDIVMNHHLQE

128
Table A2.
Sample name
6His MBP
3C+

Results from the MS analysis for the cleavage of constructs used.
Accession Cover # Peptides # Unique # AAs MW calc. Score
# Peptides
age
Peptides
[kDa] pI
Sequest
[%]
HT
MC10
70
37
2
592
66
5.21
937.84
37
MC3

72

36

1

553

61.5

5.02

880.75

36

MC7

43

17

11

407

47

5.3

86.03

17

A1AIF3

36

10

10

394

43.3

5.45

36.91

10

B7NSH9

25

6

6

353

38

5.19

22.22

6

P0C0V1

10

3

3

474

49.3

8.56

10.6

3

MC10

77

46

34

592

66

5.21

1510.32

46

MC7

30

14

2

407

47

5.3

389.2

14

P0AG67

10

5

5

557

61.1

4.98

16.45

5

P08660

10

3

3

449

48.5

5.11

10.65

3

MC10

74

40

31

592

66

5.21

740.78

40

MC7

37

13

4

407

47

5.3

198.95

13

P0AG67

18

8

8

557

61.1

4.98

27.72

8

80

45

2

592

66

5.21

1334.5

45

92

33

1

393

43.3

5.15

959.24

33

MC7

30

13

2

407

47

5.3

336.29

13

P0AG67

12

5

5

557

61.1

4.98

21.98

5

6His TEV Fort MC10
TEV+
MC7

58

27

16

592

66

5.21

838.13

27

40

19

8

407

47

5.3

799.43

19

MC18

45

4

1

83

9

4.36

464.2

4

P0A6T6

34

6

6

222

24.8

7.33

29.16

6

P0ACJ8

47

9

9

210

23.6

8.25

26.29

9

MC3

48

20

10

553

61.5

5.02

490.22

20

MC7

35

13

3

407

47

5.3

449.7

13

P0A6T6

34

7

7

222

24.8

7.33

25.01

7

A7ZSM6

2

2

2

601

66.4

6.68

10.4

2

MC7

70

35

24

407

47

5.3

1620.44

35

MC10

34

18

7

592

66

5.21

646.51

18

P0A9G6

52

16

16

434

47.5

5.31

58.66

16

A7ZML6

41

11

11

406

43.6

6.35

46.74

11

P0A932

6

3

3

379

41.7

6.06

10.47

3

A1AIF3

12

4

4

394

43.3

5.45

10.01

4

MC7

64

33

22

407

47

5.3

1241.48

33

MC10

54

24

13

592

66

5.21

674.25

24

6His MBP
Fortilin -ctrl

6His MBP
Fortilin 3C+

6His MBP
MC10
Fortilin TEV+
MC1

6His TEV
Fort TEV-

GST 3C TEV
Fort -ctrl

GST 3C TEV
Fortilin +3C
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GST 3C TEV
Fortilin
TEV+

MBP +ctrl

MC18

45

5

2

83

9

4.36

315.56

5

P0A9G6

59

19

19

434

47.5

5.31

101.88

19

A7ZML6

43

11

11

406

43.6

6.35

55.05

11

A1AIF3

15

5

5

394

43.3

5.45

15.3

5

B1XC35

15

4

4

446

49.9

4.98

13.47

4

MC7

66

38

26

407

47

5.3

1793.38

38

MC10

28

16

4

592

66

5.21

634.19

16

MC18

45

4

1

83

9

4.36

400.76

4

P0A9G6

52

17

17

434

47.5

5.31

81.6

17

A7ZML6

48

13

13

406

43.6

6.35

58.48

13

A1AIF3

14

4

4

394

43.3

5.45

13.98

4

MC3

74

42

36

553

61.5

5.02

1324.27

42

MC7

28

9

3

407

47

5.3

38.16

9

MC2

34

7

7

252

28.5

10.71

36.98

7

B1X8Q8

30

5

5

172

19

6.57

19.28

5

P03023

16

5

5

360

38.6

6.89

14.26

5

P76083

8

2

2

475

51.7

5.91

11.34

2

MBP TEV
Fort TEV-

MC3

77

37

29

553

61.5

5.02

819.19

37

MC7

32

11

3

407

47

5.3

207.07

11

MBP TEV
Fortilin
TEV+

MC3

79

40

2

553

61.5

5.02

852.73

40

MC10

76

40

2

592

66

5.21

842.68

40

MC7

30

12

2

407

47

5.3

206.49

12

MC10

64

37

5

592

66

5.21

770.37

37

P0AEX9

82

33

1

396

43.4

5.71

767.19

33

P02931

43

17

17

362

39.3

4.96

141.84

17

B1XC35

17

4

4

446

49.9

4.98

14.73

4

MC3

77

44

2

553

61.5

5.02

1152.63

44

P0AEX9

83

37

1

396

43.4

5.71

1101.93

37

P02931

52

17

17

362

39.3

4.96

166.63

17

MC7

23

7

1

407

47

5.3

54.65

7

B1XC35

34

10

10

446

49.9

4.98

46.22

10

P10384

11

4

4

446

48.5

5.3

12.86

4

OSM +ctrl

MC2

21

5

5

252

28.5

10.71

20.12

5

TEV Fortilin
3C+

MC10

53

28

17

592

66

5.21

336.42

28

MC7

52

26

14

407

47

5.3

334.93

26

MC5

67

13

1

179

20.4

4.87

257.77

13

B7LA77

24

4

4

234

24.7

9.64

12.68

4

MBP TEV-

MBP TEV+
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TEV Fortilin
from GST
3C+

B1LHD4

23

3

3

209

22.2

9.91

11.17

3

B7LHZ8

20

3

3

206

23.5

10.05

10.32

3

MC7

61

30

19

407

47

5.3

549.13

30

MC10

33

17

7

592

66

5.21

247.95

17

MC5

67

12

1

179

20.4

4.87

220.44

12

P0A9D2

46

8

8

201

22.9

6.21

69.67

8

B1IPZ4

50

8

8

177

18.9

9.7

25.09

8

P0AA25

39

3

3

109

11.8

4.88

15.87

3

B7LHZ8

21

4

4

206

23.5

10.05

14.28

4

P0A9G6

12

3

3

434

47.5

5.31

11

3
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APPENDIX B
Supplementary materials for Chapter Three – purification gels of protein
expressions
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SDS-PAGE to check purification status of proteins

Figure B1.

Purification gel of NGly56 mutant fortilin construct.

Figure B2.

Purification gel of CGly56 mutant fortilin construct.
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Figure B3.

Purification gel of NSer46 mutant fortilin construct.
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APPENDIX C
Protein amino acid & plasmid DNA sequence
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Protein amino acid sequences
WT Fortilin, No Tag (Uniprot.com)
>sp|P13693|TCTP_HUMAN Translationally controlled tumor protein OS=Homo
sapiens OX=9606 GN=TPT1 PE=1 SV=1
MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLIGGNA
SAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQR
PERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPYMI
FFKDGLEMEKC
# of amino acids – 172
Mass – 19595.32 Da
mI – 4.84
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
Ext. coefficient

12045

Abs 0.1% (=1 g/l) 0.615, assuming all pairs of Cys residues form cystines
Ext. coefficient

11920

Abs 0.1% (=1 g/l) 0.608, assuming all Cys residues are reduced
6His-TEV-Fortilin
>HHHHHHENLYFQMIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSR
TEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKD
YMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVAL
LDYREDGVTPYMIFFKDGLEMEKC
# of amino acids – 184
Mass – 21213.05 Da
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pI – 5.24
Ext. coefficient

13535

Abs 0.1% (=1 g/l) 0.638, assuming all pairs of Cys residues form cystines
Ext. coefficient

13410

Abs 0.1% (=1 g/l) 0.632, assuming all Cys residues are reduced
MBP-TEV-Fortilin
>MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH
PDKLEEKFPQ VAATGDGPDI IFWAHDRFGG YAQSGLLAEI TPDKAFQDKL
YPFTWDAVRY NGKLIAYPIAVEALSLIYNK DLLPNPPKTW EEIPALDKEL
KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK DVGVDNAGAK
AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK
VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG
LEAVNKDKPL GAVALKSYEE ELAKDPRIAA TMENAQKGEI MPNIPQMSAF
WYAVRTAVIN
AASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGIEGRENLYFQMIIYRDLISHD
EMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLIGGNASAEGPEGEGTESTVI
TGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQRPERVKPFMTGAAEQ
IKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPYMIFFKDGLEMEKC
# of amino acids – 565
Mass – 62854.17 Da
pI – 4.95
Ext. coefficient

79885

Abs 0.1% (=1 g/l) 1.271, assuming all pairs of Cys residues form cystines
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Ext. coefficient

79760

Abs 0.1% (=1 g/l) 1.269, assuming all Cys residues are reduced
6His-MBP-10N-3C-TEV-Fortilin
>HHHHHHMKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH
PDKLEEKFPQ VAATGDGPDI IFWAHDRFGG YAQSGLLAEI TPDKAFQDKL
YPFTWDAVRY NGKLIAYPIAVEALSLIYNK DLLPNPPKTW EEIPALDKEL
KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK DVGVDNAGAK
AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK
VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG
LEAVNKDKPL GAVALKSYEE ELAKDPRIAA TMENAQKGEI MPNIPQMSAF
WYAVRTAVIN AASGRQTVDE ALKDAQTNSS SNNNNNNNNN
NLGIEGRNNNNNNNNNNLEVLFQENLYFQMIIYRDLISHDEMFSDIYKIREIADGL
CLEVEGKMVSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETS
FTKEAYKKYIKDYMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIG
ENMNPDGMVALLDYREDGVTPYMIFFKDGLEMEKC
# of amino acids – 587
Mass – 65547.93
pI – 5.12
Ext. coefficient

79885

Abs 0.1% (=1 g/l) 1.219, assuming all pairs of Cys residues form cystines
Ext. coefficient

79760

Abs 0.1% (=1 g/l) 1.217, assuming all Cys residues are reduced
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GST-3C-TEV-Fortilin
>MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFEL
GLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIR
YGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLY
DALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATF
GGGDHPPKLEVLFQENLYFQMIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMV
SRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYI
KDYMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMV
ALLDYREDGVTPYMIFFKDGLEMEKC
# of amino acids – 402
Mass – 46600.74 Da
Ext. coefficient

56645

Abs 0.1% (=1 g/l) 1.216, assuming all pairs of Cys residues form cystines
Ext. coefficient

56270

Abs 0.1% (=1 g/l) 1.207, assuming all Cys residues are reduced
GST-3C-Fortilin
>MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFEL
GLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIR
YGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLY
DALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATF
GGGDHPPKLEVLFQMIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGN
IDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMK
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SIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDY
REDGVTPYMIFFKDGLEMEKC
# of amino acids – 396
pI – 5.25
Ext. coefficient

55155

Abs 0.1% (=1 g/l) 1.204, assuming all pairs of Cys residues form cystines
Ext. coefficient

54780

Abs 0.1% (=1 g/l) 1.196, assuming all Cys residues are reduced
GST-3C-GGS-Fortilin
>MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFEL
GLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIR
YGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLY
DALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATF
GGGDHPPKLEVLFQGGSMIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRT
EGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKD
YMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVAL
LDYREDGVTPYMIFFKDGLEMEKC
# of amino acids – 399
Mass – 46007.06
pI – 0.525
Ext. coefficient

55155

Abs 0.1% (=1 g/l) 1.199, assuming all pairs of Cys residues form cystines
Ext. coefficient

54780
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Abs 0.1% (=1 g/l) 1.191, assuming all Cys residues are reduced
GST-3C-GGSGGS-Fortilin
>MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFEL
GLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIR
YGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLY
DALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATF
GGGDHPPKLEVLFQGGSGGSMIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKM
VSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKK
YIKDYMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDG
MVALLDYREDGVTPYMIFFKDGLEMEKC
# of amino acids – 402
pI – 5.25
Ext. coefficient

55155

Abs 0.1% (=1 g/l) 1.194, assuming all pairs of Cys residues form cystines
Ext. coefficient

54780

Abs 0.1% (=1 g/l) 1.186, assuming all Cys residues are reduced
GST-3C-GGSGGSGGS-Fortilin
>MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFEL
GLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIR
YGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLY
DALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATF
GGGDHPPKLEVLFQGGSGGSGGSMIIYRDLISHDEMFSDIYKIREIADGLCLEVEG
KMVSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAY
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KKYIKDYMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPD
GMVALLDYREDGVTPYMIFFKDGLEMEKC
# of amino acids – 405
Mass – 46409.42
pI – 5.25
Ext. coefficient

55155

Abs 0.1% (=1 g/l) 1.188, assuming all pairs of Cys residues form cystines
Ext. coefficient

54780

Abs 0.1% (=1 g/l) 1.180, assuming all Cys residues are reduced
GGS-Fortilin
>GGSMIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLI
GGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGK
LEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGV
TPYMIFFKDGLEMEKC
# of amino acids – 175
Mass – 19796.52 Da
pI – 4.84
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. No
Trp residues means there can be 10% or more in error.
Ext. coefficient

12045

Abs 0.1% (=1 g/l) 0.608, assuming all pairs of Cys residues form cystines
Ext. coefficient

11920

Abs 0.1% (=1 g/l) 0.602, assuming all Cys residues are reduced
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Fortilin-Strep (C-terminal StrepTactin® fusion tag)
>MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLIGGN
ASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQ
RPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPY
MIFFKDGLEMEKCWSHPQFEK
# of amino acids - 180
Mass – 20,635.48 Da
pI – 4.93
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
Ext. coefficient

17545

Abs 0.1% (=1 g/l) 0.850, assuming all pairs of Cys residues form cystines
Ext. coefficient

17420

Abs 0.1% (=1 g/l) 0.844, assuming all Cys residues are reduced
Fortilin-Strep CSer46
>MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSWSHPQFEKSLIGGN
ASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQ
RPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPY
MIFFKDGLEMEKC
# of amino acids – 172
Mass – 19374.58 Da
pI – 5.07
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
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Ext. coefficient

17545Abs 0.1% (=1 g/l) 0.889, assuming all pairs of Cys

residues form cystines
Ext. coefficient

17420

Abs 0.1% (=1 g/l) 0.883, assuming all Cys residues are reduced
Fortilin-Strep NSer46
>MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSWSHPQFEKSLIGGN
ASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQ
RPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPY
MIFFKDGLEMEKC
# of amino acids - 172
Mass – 19734.58 Da
pI – 5.07
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
Ext. coefficient

17545

Abs 0.1% (=1 g/l) 0.889, assuming all pairs of Cys residues form cystines
Ext. coefficient

17420

Abs 0.1% (=1 g/l) 0.883, assuming all Cys residues are reduced
Fortilin-Strep CGly56
>MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLIGGN
ASAEGWSHPQFEKTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEE
QRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPY
MIFFKDGLEMEKC
# of amino acids – 172
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Mass – 19848.73 Da
pI – 5.16
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
Ext. coefficient

17545

Abs 0.1% (=1 g/l) 0.884, assuming all pairs of Cys residues form cystines
Ext. coefficient

17420

Abs 0.1% (=1 g/l) 0.878, assuming all Cys residues are reduced
Fortilin-Strep NGly56
>MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLWSHP
QFEKGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQ
RPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPY
MIFFKDGLEMEKC
# of amino acids – 172
Mass – 19935.77 Da
pI – 4.99
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
Ext. coefficient

17545

Abs 0.1% (=1 g/l) 0.880, assuming all pairs of Cys residues form cystines
Ext. coefficient

17420

Abs 0.1% (=1 g/l) 0.874, assuming all Cys residues are reduced
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Plasmid DNA sequences
pASG-IBA3 vector (IBA LifeSciences)

Figure C1. Plasmid vector map from IBA Lifesciences (ibalifesciences.com/details/product/5-4003-001.html)
DNA sequence:
>TCACGGATCTCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAG
CGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGT
TCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCAC
CTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCG
CCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTA
TCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATT
TAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTCAGGTGGCACTTTTCGGGGAAA
TGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAAC
CCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATT
CCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGA
AGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTC
GCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATT
GACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGT
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CACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATA
ACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATG
GGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGA
CACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTT
CCCGGCAACAATTGATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCG
GCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGCTCTCGCGGTATCATTGCAGCACTGGG
GCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAA
ATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAGGAATTAATGATGTCTCGTTTAGAT
AAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGTAA
ACTCGCCCAGAAGCTAGGTGTAGAGCAGCCTACATTGTATTGGCATGTAAAAAATAAGCGGGCTTTGCTCG
ACGCCTTAGCCATTGAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAA
GATTTTTTACGTAATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGCGATGGAGCAAAAGTACA
TTTAGGTACACGGCCTACAGAAAAACAGTATGAAACTCTCGAAAATCAATTAGCCTTTTTATGCCAACAAG
GTTTTTCACTAGAGAATGCATTATATGCACTCAGCGCAGTGGGGCATTTTACTTTAGGTTGCGTATTGGAA
GATCAAGAGCATCAAGTCGCTAAAGAAGAAAGGGAAACACCTACTACTGATAGTATGCCGCCATTATTACG
ACAAGCTATCGAATTATTTGATCACCAAGGTGCAGAGCCAGCCTTCTTATTCGGCCTTGAATTGATCATAT
GCGGATTAGAAAAACAACTTAAATGTGAAAGTGGGTCTTAAAAGCAGCATAACCTTTTTCCGTGATGGTAA
CTTCACTAGTTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGA
GTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGC
GCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTA
CCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCC
GTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAG
TGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCG
CAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG
ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAA
GCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCT
GTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAA
AAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGACCCGACACC
ATCGAATGGCCAGATGATTAATTCCTAATTTTTGTTGACACTCTATCATTGATAGAGTTATTTTACCACTC
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CCTATCAGTGATAGAGAAAAGTGAAATGAATAGTTCGACAAAAATCTAGAAATAATTTTGTTTAACTTTAA
GAAGGAGATATACAAATGAGAGACGCTGCAGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATT
CATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAG
TTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGA
GCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCACTAA
AGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCAGGA
ATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAG
TCGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAA
TCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCTCCTTTCGCTTTCTTC
CCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCG
ATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACCTCGAGCGTCTCAGG
GAGCGCTTGGAGCCACCCGCAGTTCGAAAAATAAGGGAGCCACCCGCAAGCTTGACCTGTGAAGTGAAAAA
TGGCGCACATTGTGCGACATTTTTTTTGTCTGCCGTTTACCGCTACTGCG
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pD441-SR Vector (ATUM)

Figure C2. pD441-SR plasmid vector map from ATUM
(https://www.atum.bio/eCommerce/catalog/datasheet/117).
DNA sequence:
> 1 CCCGTAGAAA AGATCAAAGG ATCTTCTTGA GATCCTTTTT TTCTGCGCGT AATCTGCTGC
61 TTGCAAACAA AAAAACCACC GCTACCAGCG GTGGTTTGTT TGCCGGATCA
AGAGCTACCA
121 ACTCTTTTTC CGAAGGTAAC TGGCTTCAGC AGAGCGCAGA TACCAAATAC
TGTTCTTCTA
181 GTGTAGCCGT AGTTAGCCCA CCACTTCAAG AACTCTGTAG CACCGCCTAC
ATACCTCGCT
241 CTGCTAATCC TGTTACCAGT GGCTGCTGCC AGTGGCGATA AGTCGTGTCT
TACCGGGTTG
301 GACTCAAGAC GATAGTTACC GGATAAGGCG CAGCGGTCGG GCTGAACGGG
GGGTTCGTGC
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361 ACACAGCCCA GCTTGGAGCG AACGACCTAC ACCGAACTGA GATACCTACA
GCGTGAGCTA
421 TGAGAAAGCG CCACGCTTCC CGAAGGGAGA AAGGCGGACA GGTATCCGGT
AAGCGGCAGG
481 GTCGGAACAG GAGAGCGCAC GAGGGAGCTT CCAGGGGGAA ACGCCTGGTA
TCTTTATAGT
541 CCTGTCGGGT TTCGCCACCT CTGACTTGAG CGTCGATTTT TGTGATGCTC
GTCAGGGGGG
601 CGGAGCCTAT GGAAAAACGC CAGCAACGCG GCCTTTTTAC GGTTCCTGGC
CTTTTGCTGG
661 CCTTTTGCTC ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA
CCGTATTACC
721 GCCTTTGAGT GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG
CGAGTCAGTG
781 AGCGAGGAAG CGGAAGGCGA GAGTAGGGAA CTGCCAGGCA TCAAACTAAG
CAGAAGGCCC
841 CTGACGGATG GCCTTTTTGC GTTTCTACAA ACTCTTTCTG TGTTGTAAAA
CGACGGCCAG
901 TCTTAAGCTC GGGCCCCCTG GGCGGTTCTG ATAACGAGTA ATCGTTAATC
CGCAAATAAC
961 GTAAAAACCC GCTTCGGCGG GTTTTTTTAT GGGGGGAGTT TAGGGAAAGA
GCATTTGTCA
1021 GAATATTTAA GGGCGCCTGT CACTTTGCTT GATATATGAG AATTATTTAA
CCTTATAAAT
1081 GAGAAAAAAG CAACGCACTT TAAATAAGAT ACGTTGCTTT TTCGATTGAT
GAACACCTAT
1141 AATTAAACTA TTCATCTATT ATTTATGATT TTTTGTATAT ACAATATTTC
TAGTTTGTTA
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1201 AAGAGAATTA AGAAAATAAA TCTCGAAAAT AATAAAGGGA AAATCAGTTT
TTGATATCAA
1261 AATTATACAT GTCAACGATA ATACAAAATA TAATACAAAC TATAAGATGT
TATCAGTATT
1321 TATTATGCAT TTAGAATAAA TTTTGTGTCG CCCTTAATTG TGAGCGGATA
ACAATTACGA
1381 GCTTCATGCA CAGTGAAATC ATGAAAAATT TATTTGCTTT GTGAGCGGAT
AACAATTATA
1441 ATATGTGGAA TTGTGAGCGC TCACAATTCC ACAACGGTTT CCCTCTAGAA
ATAATTTTGT
1501 TTAACTTTTA AGGAGGTAAA AAATGATTAT CTACCGTGAT TTGATTAGCC
ACGACGAAAT
1561 GTTTAGCGAT ATCTACAAGA TCCGCGAGAT CGCAGACGGC CTGTGCCTCG
AAGTTGAGGG
1621 TAAAATGGTG TCTCGTACCG AAGGCAATAT CGACGATTCC CTGATCGGCG
GCAATGCGAG
1681 CGCCGAGGGT TGGAGCCATC CGCAAGGTCA GAAAACCGTT ATCACGGGTG
TCGATATTGT
1741 CATGAACCAC CATCTGCAGG AAACCAGCTT TACTAAAGAG GCGTACAAAA
AGTACATTAA
1801 AGACTACATG AAAAGCATTA AGGGCAAACT GGAAGAACAG CGCCCAGAGC
GTGTGAAGCC
1861 GTTTATGACC GGTGCGGCAG AGCAAATCAA GCACATTCTG GCTAACTTTA
AGAACTATCA
1921 ATTCTTCATT GGTGAGAACA TGAATCCGGA CGGTATGGTT GCGCTGCTGG
ATTATCGTGA
1981 GGACGGTGTG ACGCCGTATA TGATTTTCTT CAAAGATGGC CTGGAAATGG
AAAAGTGTTA
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2041 ATAAGGTTGA CCCCAAGGGC GACACCCCCT AATTAGCCCG GGCGAAAGGC
CCAGTCTTTC
2101 GACTGAGCCT TTCGTTTTAT TTGATGCCTG GCAGTTCCCT ACTCTCGCAT
GGGGAGTCCC
2161 CACACTACCA TCGGCGCTAC GGCGTTTCAC TTCTGAGTTC GGCATGGGGT
CAGGTGGGAC
2221 CACCGCGCTA CTGCCGCCAG GCAAACAAGG GGTGTTATGA GCCATATTCA
GGTATAAATG
2281 GGCTCGCGAT AATGTTCAGA ATTGGTTAAT TGGTTGTAAC ACTGACCCCT
ATTTGTTTAT
2341 TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA
TAAATGCTTC
2401 AATAATATTG AAAAAGGAAG AATATGAGCC ATATTCAACG GGAAACGTCG
AGGCCGCGAT
2461 TAAATTCCAA CATGGATGCT GATTTATATG GGTATAAATG GGCTCGCGAT
AATGTCGGGC
2521 AATCAGGTGC GACAATCTAT CGCTTGTATG GGAAGCCCGA TGCGCCAGAG
TTGTTTCTGA
2581 AACATGGCAA AGGTAGCGTT GCCAATGATG TTACAGATGA GATGGTCAGA
CTAAACTGGC
2641 TGACGGAATT TATGCCACTT CCGACCATCA AGCATTTTAT CCGTACTCCT
GATGATGCAT
2701 GGTTACTCAC CACTGCGATC CCCGGAAAAA CAGCGTTCCA GGTATTAGAA
GAATATCCTG
2761 ATTCAGGTGA AAATATTGTT GATGCGCTGG CAGTGTTCCT GCGCCGGTTG
CACTCGATTC
2821 CTGTTTGTAA TTGTCCTTTT AACAGCGATC GCGTATTTCG CCTCGCTCAG
GCGCAATCAC
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2881 GAATGAATAA CGGTTTGGTT GATGCGAGTG ATTTTGATGA CGAGCGTAAT
GGCTGGCCTG
2941 TTGAACAAGT CTGGAAAGAA ATGCATAAAC TTTTGCCATT CTCACCGGAT
TCAGTCGTCA
3001 CTCATGGTGA TTTCTCACTT GATAACCTTA TTTTTGACGA GGGGAAATTA
ATAGGTTGTA
3061 TTGATGTTGG ACGAGTCGGA ATCGCAGACC GATACCAGGA TCTTGCCATC
CTATGGAACT
3121 GCCTCGGTGA GTTTTCTCCT TCATTACAGA AACGGCTTTT TCAAAAATAT
GGTATTGATA
3181 ATCCTGATAT GAATAAATTG CAGTTTCATT TGATGCTCGA TGAGTTTTTC
TAAGCGGCGC
3241 GCCATCGAAT GGCGCAAAAC CTTTCGCGGT ATGGCATGAT AGCGCCCGGA
AGAGAGTCAA
3301 TTCAGGGTGG TGAATATGAA ACCAGTAACG TTATACGATG TCGCAGAGTA
TGCCGGTGTC
3361 TCTTATCAGA CCGTTTCCCG CGTGGTGAAC CAGGCCAGCC ACGTTTCTGC
GAAAACGCGG
3421 GAAAAAGTGG AAGCGGCGAT GGCGGAGCTG AATTACATTC CCAACCGCGT
GGCACAACAA
3481 CTGGCGGGCA AACAGTCGTT GCTGATTGGC GTTGCCACCT CCAGTCTGGC
CCTGCACGCG
3541 CCGTCGCAAA TTGTCGCGGC GATTAAATCT CGCGCCGATC AACTGGGTGC
CAGCGTGGTG
3601 GTGTCGATGG TAGAACGAAG CGGCGTCGAA GCCTGTAAAG CGGCGGTGCA
CAATCTTCTC
3661 GCGCAACGCG TCAGTGGGCT GATCATTAAC TATCCGCTGG ATGACCAGGA
TGCCATTGCT
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3721 GTGGAAGCTG CCTGCACTAA TGTTCCGGCG TTATTTCTTG ATGTCTCTGA
CCAGACACCC
3781 ATCAACAGTA TTATTTTCTC CCATGAGGAC GGTACGCGAC TGGGCGTGGA
GCATCTGGTC
3841 GCATTGGGTC ACCAGCAAAT CGCGCTGTTA GCGGGCCCAT TAAGTTCTGT
CTCGGCGCGT
3901 CTGCGTCTGG CTGGCTGGCA TAAATATCTC ACTCGCAATC AAATTCAGCC
GATAGCGGAA
3961 CGGGAAGGCG ACTGGAGTGC CATGTCCGGT TTTCAACAAA CCATGCAAAT
GCTGAATGAG
4021 GGCATCGTTC CCACTGCGAT GCTGGTTGCC AACGATCAGA TGGCGCTGGG
CGCAATGCGC
4081 GCCATTACCG AGTCCGGGCT GCGCGTTGGT GCGGATATCT CGGTAGTGGG
ATACGACGAT
4141 ACCGAAGATA GCTCATGTTA TATCCCGCCG TTAACCACCA TCAAACAGGA
TTTTCGCCTG
4201 CTGGGGCAAA CCAGCGTGGA CCGCTTGCTG CAACTCTCTC AGGGCCAGGC
GGTGAAGGGC
4261 AATCAGCTGT TGCCAGTCTC ACTGGTGAAA AGAAAAACCA CCCTGGCGCC
CAATACGCAA
4321 ACCGCCTCTC CCCGCGCGTT GGCCGATTCA TTAATGCAGC TGGCACGACA
GGTTTCCCGA
4381 CTGGAAAGCG GGCAGTGACT CATGACCAAA ATCCCTTAAC GTGAGTTACG
CGCGCGTCGT
4441 TCCACTGAGC GTCAGAC
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APPENDIX D
Filenames and parameters for NMR experiments
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Table D1.

Filenames and parameters for NMR experiments.

Filename

B0

ns

td1

td2

d1

T

15N_fortilin_20mMTrisHCl_Ca_18102019_MSC

600

8

2048

400

1

308

15N_fortilin_50mMNaCl_Hemin_21012020_MSC

600

16

2048

400

1

308

15N_fortilin_50mMNaCl_Hemin11CO9_24012020

600

8

2048

400

1

308

15N_fortilin_50mMNaCl_HeminDHA_22012020_MSC

600

8

2048

400

1

308

15N_fortilin007_A26A3Titr_10May2021_MSC

600

16

2048

400

1

298

15N_fortilinstrep004_ArtTitr_03May2021_MSC

600

16

2048

400

1

298

15Nfortilin50mMNaCl_DHA_17092019mc

600

8

2048

400

1

308

Lisa_004-TCTP_210427

800

16

2048

400

1

298

B0 – static magnetic field strength in MHz
ns – number of scans
td1 – number of FID points in proton frequency
td1 – number of FID points in nitrogen frequency
d1 – interscan delay
T – temperature (K)

